10-Q

Table of Contents ​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

​

(Mark One)

☒ **** QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended September 30, 2025

or

**☐**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from **** to

Commission File Number: 001-40021

AEON Biopharma, Inc.

(Exact name of registrant as specified in its charter)

​

​	​
Delaware	85-3940478
(State or other jurisdiction of <br>incorporation or organization)	(I.R.S. Employer <br>Identification Number)

​

5 Park Plaza

Suite 1750

Irvine , CA **** 92614

(Address of Principal Executive Offices)

( 949 ) 354-6499

(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ☒    No   ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

				​	​
Large accelerated filer	☐	Accelerated filer	☐	​	​
​	​	​	​	​	​
Non-accelerated filer	☒	Smaller reporting company	☒	Emerging growth company	☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ☐    No  ☒

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​
Title of Each Class	Trading symbol	Name of Exchange on which registered
Class A common stock, $0.0001 par value per share	AEON	NYSE American

​

As of November 10, 2025, there were 11,838,447 of the registrant’s shares of Class A common stock, $0.0001 par value per share, outstanding.

​

Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Report”) contains certain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements other than statements of historical facts contained in this Report, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Report and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the risks, uncertainties and assumptions. These forward-looking statements are subject to numerous risks, including, without limitation, the following:

●	the projected financial information, anticipated growth rate and market opportunities of AEON Biopharma, Inc. (“AEON”);
●	the ability to maintain the listing of Class A common stock on NYSE American;
---	---
●	AEON’s public securities’ potential liquidity and trading;
---	---
●	AEON’s ability to raise financing in the future and to continue as a going concern;
---	---
●	AEON’s ability to obtain stockholder approval and/or satisfy customary closing conditions for its private placement or convertible notes exchange;
---	---
●	AEON’s success in retaining or recruiting, or changes required in officers, key employees, scientific personnel or directors;
---	---
●	factors relating to the business, operations and financial performance of AEON;
---	---
●	the initiation, cost, timing, progress and results of research and development activities, preclinical studies or clinical trials with respect to AEON’s current and potential future product candidates;
---	---
●	AEON’s ability to identify, develop and commercialize its main product candidate, botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection (“ABP-450”);
---	---
●	AEON’s ability to obtain a Biologics License Application (“BLA”) for therapeutic uses of ABP-450;
---	---
●	AEON’s ability to advance its current and potential future product candidates into, and successfully complete, preclinical studies and clinical trials;
---	---
●	AEON’s ability to obtain and maintain regulatory approval of its current and potential future product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate;
---	---
●	AEON’s ability to obtain and maintain intellectual property protection for its technologies and any of its product candidates;
---	---
●	AEON’s ability to successfully commercialize its current and any potential future product candidates;
---	---
●	the rate and degree of market acceptance of AEON’s current and any potential future product candidates;
---	---
●	regulatory developments in the United States and international jurisdictions;
---	---
●	potential liability, lawsuits and penalties related to AEON’s technologies, product candidates and current and future relationships with third parties;
---	---
●	AEON’s ability to effectively manage the growth of its operations;
---	---

Table of Contents

●	AEON’s ability to contract with third-party suppliers and manufacturers and their ability to perform adequately under those arrangements, particularly its license and supply agreement with Daewoong Pharmaceutical Co., LTD. (the “Daewoong Agreement”);
●	anticipated Biosimilar Biological Product Development (“BPD”) meetings with the FDA;
---	---
●	anticipated results from our analytical studies;
---	---
●	AEON’s ability to compete effectively with existing competitors and new market entrants;
---	---
●	potential effects of extensive government regulation;
---	---
●	AEON’s future financial performance and capital requirements;
---	---
●	AEON’s ability to implement and maintain effective internal controls;
---	---
●	the impact of supply chain disruptions; and
---	---
●	the impact of macroeconomic developments beyond our control, such as health epidemics or pandemics, macro-economic uncertainties, tariffs, social unrest, hostilities, natural disasters or other catastrophic events, on AEON’s business.
---	---

The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed in this Report, may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included elsewhere in this Report are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements included elsewhere in this Report. In addition, even if our results of operations, financial condition and liquidity, and events in the industry in which we operate, are consistent with the forward-looking statements included elsewhere in this Report, they may not be predictive of results or developments in future periods.

Any forward-looking statement that we make in this Report speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this Report. For all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Reform Act.

As used in this Report, unless otherwise stated or the context otherwise requires: “we,” “us,” “our,” “AEON,” the “Company,” and similar references refer to AEON Biopharma, Inc. and its subsidiaries, and “common stock” refers to our Class A common stock.

​

​

​

​

​

Table of Contents TABLE OF CONTENTS

​

​		​		Page
​	​	​	​	​
Part I	​	Financial Information	​	​
​	​	​	​	​
Item 1.	​	Financial Statements	​	1
​	​	​	​	​
​	​	Condensed Consolidated Balance Sheets	​	1
​	​	​	​	​
​	​	Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income	​	2
​	​	​	​	​
​	​	Condensed Consolidated Statements of Stockholders’ Deficit	​	3
​	​	​	​	​
​	​	Condensed Consolidated Statements of Cash Flows	​	4
​	​	​	​	​
​	​	Notes to Condensed Consolidated Financial Statements	​	5
​	​	​	​	​
Item 2.	​	Management’s Discussion and Analysis of Financial Condition and Results of Operations	​	26
​	​	​	​	​
Item 3.	​	Quantitative and Qualitative Disclosures about Market Risk	​	37
​	​	​	​	​
Item 4.	​	Controls and Procedures	​	37
​	​	​	​	​
Part II	​	Other Information	​	​
​	​	​	​	​
Item 1.	​	Legal Proceedings	​	39
​	​	​	​	​
Item 1A.	​	Risk Factors	​	39
​	​	​	​	​
Item 2.	​	Unregistered Sales of Equity Securities and Use of Proceeds	​	39
​	​	​	​	​
Item 3.	​	Defaults Upon Senior Securities	​	39
​	​	​	​	​
Item 4.	​	Mine Safety Disclosures	​	39
​	​	​	​	​
Item 5.	​	Other Information	​	40
​	​	​	​	​
Item 6.	​	Exhibits	​	40
​	​	​	​	​
Exhibit Index			​	41
​			​	​
Signatures			​	43

​

​

​ ​

Table of Contents PART I —FINANCIAL INFORMATION

Item 1. Financial Statements

​

AEON BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEET S

(in thousands, except share data and par value amounts)

​

​	​	​	​	​	​	​	​
​	​	September 30,		​	December 31,		​
​	****	2025		****	2024		​
​	​	(Unaudited)		​	​		​
ASSETS		​			​		​
Current assets:		​			​		​
Cash and cash equivalents	​	$	5,927	​	$	13	​
Prepaid expenses and other current assets	​		1,485	​		1,577	​
Total current assets	​		7,412	​		1,590	​
Property and equipment, net	​		181	​		235	​
Operating lease right-of-use asset	​		1,112	​		1,288	​
Other assets	​		29	​		29	​
Total assets	​	$	8,734	​	$	3,142	​
LIABILITIES AND STOCKHOLDERS' DEFICIT	​			​			​
Current liabilities:	​			​			​
Accounts payable	​	$	2,525	​	$	5,910	​
Accrued clinical trials expenses	​		1,524	​		3,571	​
Accrued compensation	​		1,547	​		1,068	​
Other accrued expenses	​		2,632	​		3,600	​
Total current liabilities	​		8,228	​		14,149	​
Convertible notes at fair value, including related party amount of $17,051 and $11,689, at September 30, 2025 and December 31, 2024, respectively	​		17,051	​		11,689	​
Operating lease liability	​		957	​		1,145	​
Warrant liability	​	​	2,338	​	​	1,187	​
Contingent consideration liability	​	​	32	​	​	3,541	​
Total liabilities	​		28,606	​		31,711	​
Commitments and contingencies (Note 6)	​			​			​
Stockholders’ Deficit:	​			​		​	​
Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at September 30, 2025 and December 31, 2024, and 11,643,786 and 555,511 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	​		9	​		4	​
Additional paid-in capital	​		413,801	​		403,024	​
Accumulated deficit	​		(433,682)	​		(431,597)	​
Total stockholders' deficit	​		(19,872)	​		(28,569)	​
Total liabilities and stockholders' deficit	​	$	8,734	​	$	3,142	​

​

​

See accompanying notes to the condensed consolidated financial statements

​

​

​

​

​

​

​

​

​

​ 1

Table of Contents ​

​

AEON BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME

(in thousands, except share and per share data) (Unaudited)

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	****	Three Months Ended					​	Nine Months Ended					​
​	​	September 30,					​	September 30,					​
​	​	2025			2024		​	2025			2024		​
Operating expenses:		​	​		​	​	​	​	​	​	​		​
Selling, general and administrative	​	$	1,933	​	$	3,044	​	$	8,316	​	$	11,014	​
Research and development	​		597	​		972	​		2,485	​		11,144
Change in fair value of contingent consideration	​		(37)	​		—	​		(3,509)	​		(97,464)
Total operating costs and expenses	​		2,493	​		4,016	​		7,292	​		(75,306)
(Loss) income from operations	​		(2,493)	​		(4,016)	​		(7,292)	​		75,306
Other (loss) income:	​			​			​			​
Change in fair value of convertible notes	​		(1,877)	​		(1,878)	​		(5,362)	​		(170)
Change in fair value of warrants	​		(236)	​		(377)	​		85,950	​		(15,376)
Loss on issuance of warrants	​	​	—	​	​	—	​	​	(75,644)	​		—
Loss on embedded forward purchase agreements and derivative liabilities, net	​	​	—	​	​	81	​	​	—	​		(19,931)
Other income, net	​		68	​		19	​		263	​		94
Total other (loss) income, net	​		(2,045)	​		(2,155)	​		5,207	​		(35,383)
(Loss) income before taxes	​		(4,538)	​		(6,171)	​		(2,085)	​		39,923
Income taxes	​		—	​		—	​		—	​		—
Net (loss) income	​	$	(4,538)	​	$	(6,171)	​	$	(2,085)	​	$	39,923	​
Basic net (loss) income per share	​	$	(0.39)	​	$	(11.24)	​	$	(0.23)	​	$	74.53	​
Diluted net (loss) income per share	​	$	(0.39)	​	$	(11.24)	​	$	(0.23)	​	$	69.53	​
Weighted average shares of common stock outstanding used to compute basic net (loss) income per share	​	​	11,634,946	​	​	549,175	​	​	8,931,566	​	​	535,693	​
Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share	​		11,634,946	​		549,175	​		8,931,566	​		574,216

​

​

​

​

​

​

​

​

​

​

​

​

​

See accompanying notes to the condensed consolidated financial statements

​ 2

Table of Contents ​

AEON BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(in thousands, except share data) (Unaudited)

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	****	​	****	​	​	****	Additional		****	​	​	****	​	​	****	Total
​	​	Common Stock				​	Paid-in		​	Subscription		​	Accumulated		​	Stockholders'
​	​	Shares	​	Amount		​	Capital		​	Receivables		​	Deficit		​	Deficit
Balance as of January 1, 2025		555,511	​	$	4	​	$	403,024	​	$	—	​	$	(431,597)	​	$	(28,569)
Net loss		—	​		—	​		—	​		—	​		(2,085)	​		(2,085)
Issuance of shares and reclassification of liability related to cashless warrant exercises		10,869,856	​		5	​		6,884	​		—	​		—	​		6,889
Issuance of shares related to at-the-market offering, net		218,419	​		—	​		168	​		—	​		—	​		168
Stock-based compensation expense	​	—	​		—	​		3,725	​		—	​		—	​		3,725
Balance as of September 30, 2025		11,643,786	​	$	9	​	$	413,801	​	$	—	​	$	(433,682)	​	$	(19,872)
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
Balance as of January 1, 2024		516,404	​	$	4	​	$	381,264	​	$	(60,710)	​	$	(473,602)	​	$	(153,044)
Net income	​	—	​		—	​		—	​		—	​		39,923	​	​	39,923
Termination of Forward Purchase Agreements	​	—	​		—	​		—	​		60,710	​		—	​	​	60,710
Issuance of shares and reclassification of liability related to cashless warrant exercises	​	27,310	​		—	​		14,979	​		—	​		—	​	​	14,979
Issuance of shares related to at-the-market offering, net	​	916	​	​	—	​	​	50	​	​	—	​	​	—	​	​	50
Issuance of common stock	​	5,556	​	​	—	​	​	384	​	​	—	​	​	—	​	​	384
Stock-based compensation expense	​	—	​		—	​		4,908	​		—	​		—	​	​	4,908
Balance as of September 30, 2024		550,186	​	$	4	​	$	401,585	​	$	—	​	$	(433,679)	​	$	(32,090)

​

​

​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	****	​	****	​	​	****	Additional		****	​	​	****	​	​	****	Total
​	​	Common Stock				​	Paid-in		​	Subscription		​	​	Accumulated	​	Stockholders'
​	​	Shares	​	Amount		​	Capital		​	Receivables		​	Deficit		​	Deficit
Balance as of July 1, 2025		11,537,870	​	$	9	​	$	413,283	​	$	—	​	$	(429,144)	​	$	(15,852)
Net loss		—	​	$	—	​	$	—	​	$	—	​	$	(4,538)	​		(4,538)
Issuance of shares and reclassification of liability related to cashless warrant exercises	​	—	​	$	—	​	$	20	​	$	—	​	$	—	​	​	20
Issuance of shares related to at-the-market offering, net	​	105,916	​	$	—	​	$	84	​	$	—	​	$	—	​	​	84
Stock-based compensation expense	​	—	​	$	—	​	$	414	​	$	—	​	$	—	​	​	414
Balance as of September 30, 2025		11,643,786	​	$	9	​	$	413,801	​	$	—	​	$	(433,682)	​	$	(19,872)
​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​	​
Balance as of July 1, 2024		543,714	​	$	4	​	$	399,557	​	$	—	​	$	(427,508)	​	$	(27,947)
Net loss		—	​		—	​		—	​		—	​		(6,171)	​		(6,171)
Issuance of shares related to cashless warrant exercises	​	—	​	​	—	​	​	—	​	​	—	​	​	—	​	​	—
Issuance of shares related to at-the-market offering, net	​	916	​	​	—	​	​	50	​	​	—	​	​	—	​	​	50
Issuance of common stock	​	5,556	​	​	—	​	​	384	​	​	—	​	​	—	​	​	384
Stock-based compensation expense	​	—	​	​	—	​	​	1,594	​	​	—	​	​	—	​	​	1,594
Balance as of September 30, 2024		550,186	​	$	4	​	$	401,585	​	$	—	​	$	(433,679)	​	$	(32,090)

​

​

​

See accompanying notes to the condensed consolidated financial statements

​

​ 3

Table of Contents AEON BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except per share data) (Unaudited)

​

​	​	​	​	​	​	​
​	****	Nine Months Ended
​	​	September 30,
​	​	2025		​	2024
Cash flows from operating activities:		​	​	​	​	​
Net income	​	$	(2,085)	​	$	39,923
Adjustments to reconcile net income to net cash used in operating activities:	​		​	​		​
Depreciation	​		58	​		74
Stock-based compensation expense	​	​	3,725	​		4,908
Loss on issuance of warrants	​		75,644	​		—
Change in fair value of convertible notes	​	​	5,362	​		170
Change in fair value of warrants	​	​	(85,950)	​		15,376
Change in fair value of embedded forward purchase agreements and derivative liabilities	​	​	—	​		19,931
Change in fair value of contingent consideration	​		(3,509)	​		(97,464)
Changes in operating assets and liabilities:	​		​	​	​	​
Prepaid expenses and other current assets	​		93	​		(770)
Accounts payable	​		(3,385)	​		1,242
Accrued expenses and other liabilities	​		(2,537)	​		(3,181)
Other assets and liabilities	​		(12)	​		120
Net cash used in operating activities	​		(12,596)	​		(19,671)
Cash flows from investing activities:	​			​		​
Purchases of property and equipment	​		(4)	​		—
Net cash used in investing activities	​		(4)	​		—
Cash flows from financing activities:	​			​		​
Proceeds from issuance of convertible notes	​		—	​		15,000
Proceeds from issuance of at-the-market shares, net	​	​	168	​	​	50
Proceeds from issuance of public offering shares, net	​	​	18,346	​	​	—
Net cash provided by financing activities	​		18,514	​		15,050
Net increase (decrease) in cash	​		5,914	​		(4,621)
Cash and cash equivalents at beginning of period	​		13	​		5,158
Cash and cash equivalents at end of period	​	$	5,927	​	$	537
Supplemental disclosure of cash flow information:	​			​		​
Non-cash financing activities:	​			​		​
Cashless warrant exercises	​	$	6,884	​	$	—

​

​

​

​

​

​

​

​

See accompanying notes to the condensed consolidated financial statements

​ 4

Table of Contents AEON BIOPHARMA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Organization

Description of Business

AEON Biopharma, Inc. (“AEON” or the “Company”) is a biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection (“ABP-450”), as a biosimilar to BOTOX® for debilitating medical conditions. The Company is headquartered in Irvine, California.

On July 21, 2023 (the “Closing Date”), the Company completed the acquisition of AEON Biopharma Sub, Inc. (formerly known as AEON Biopharma, Inc.) (“Old AEON”) pursuant to the definitive agreement dated December 12, 2022 (the “Business Combination Agreement”), as amended April 27, 2023, by and among Priveterra Acquisition Corp. (“Priveterra”), Priveterra’s wholly-owned subsidiary, Priveterra Merger Sub, Inc., and Old AEON (the “Merger”). On the Closing Date, Old AEON merged with Priveterra Merger Sub, Inc., with Old AEON surviving the merger as a wholly-owned subsidiary of the Company. Also on the Closing Date, the Company changed its name from “Priveterra Acquisition Corp.” to “AEON Biopharma, Inc.” and is referred to herein as “AEON,” or the “Company.”

The Company’s Class A common stock is trading on NYSE American under the symbol “AEON.”

Reverse Stock Split

On February 24, 2025, following a Special Meeting of Shareholders, the board of directions of the Company (the “Board”) approved the filing of a Certificate of Amendment to the Certificate of Incorporation to effect a reverse stock split at a split ratio of 1-for-72 (the “Reverse Stock Split”). As a result of the Reverse Stock Split, each 72 pre-split shares of Common Stock outstanding was automatically combined into one new share of Common Stock without any action on the part of the holders. The Reverse Stock Split affected all of the Company’s stockholders uniformly and did not affect any stockholder’s percentage ownership interests in the Company. No fractional shares were issued in connection with the Reverse Stock Split. In lieu of fractional shares, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the effective time of the Reverse Stock Split (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) instead received a number of shares rounded up to the nearest whole share. Proportional adjustments were made to the number of shares of Common Stock issuable upon exercise or conversion of the Company’s outstanding equity awards and warrants, as well as the applicable exercise price, except in cases where the applicable agreement provides otherwise. All share and per share amounts in the accompanying condensed consolidated financial statements have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.

Liquidity and Going Concern

The accompanying condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern. The Company has experienced recurring losses from operations and has a net capital deficiency and negative cash flows from operations since its inception. As of September 30, 2025, the Company reported cash and cash equivalents of $5.9 million and an accumulated deficit of $433.7 million. The Company expects to incur losses and use cash in its operations for the foreseeable future.

On May 3, 2024, the Company announced preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints. The Company originally intended to pursue submission of an Original BLA seeking one or more potential therapeutic indications for ABP-450. However, in May 2024, the Company announced the discontinuation of its Phase 2 clinical trials for episodic and chronic migraine in order to implement certain cash preservation measures.

On July 9, 2024, the Company announced a strategic reprioritization to pursue a Section 351(k) biosimilar regulatory pathway for ABP-450, using AbbVie Inc.’s product Botox as a proposed reference product. The Company held an initial meeting with the Food and Drug Administration (the “FDA”) in the third quarter of 2024 during which it aligned with the FDA on next steps to develop a Botox biosimilar. The Company commenced analytical studies in the fourth quarter of 2024 to prepare for an anticipated, and now 5

Table of Contents confirmed Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA to review the results from the analytical studies, including comparative primary structure analysis and select functional analyses, on November 19, 2025.

On August 14, 2024, the Company entered into an “at-the-market” sales agreement with Leerink Partners LLC (“Leerink Partners”) relating to an at-the-market offering program (the “ATM”), pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of common stock, registered pursuant to a shelf registration statement on Form S-3 (No. 333-281562) (as amended and supplemented, the “Registration Statement”) that the Securities and Exchange Commission (the “SEC”) declared effective on August 21, 2024, having aggregate gross proceeds of up to $50.0 million through Leerink Partners as sales agent. Any sales by us pursuant to the Registration Statement, including any sales pursuant to the ATM, will be subject to any limits imposed under applicable law, including General Instructions I.B.1 and I.B.6 of Form S-3. Under the ATM, Leerink Partners is entitled to commission at a rate equal to 3.0% of the gross proceeds from sales of shares of common stock under the ATM. For the three months ended September 30, 2025, there were 105,916 shares issued under the ATM for net proceeds of approximately $84,000. As of September 30, 2025, the cumulative shares issued under the ATM were 379,010 shares, net proceeds were received of approximately $0.3 million, and approximately $49.7 million of common stock remains available to be sold under the ATM. The Company may cancel its at-the-market program at any time upon prior notice, pursuant to its terms.

The commencement of additional studies, preparation for anticipated BPD meetings and any further development of ABP-450 would require additional funding in the form of equity financings or debt. There can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be commercially acceptable. Furthermore, the use of equity as a source of financing would dilute existing shareholders. The Company is actively attempting to secure additional capital to fund its operations. However, there can be no assurance that the Company will be able to raise additional capital on commercially reasonable terms or at all. As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that these condensed consolidated financial statements are issued.

The preparation of these condensed consolidated financial statements does not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of the Company’s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

The Company’s future operations are highly dependent on a combination of factors, including (1) the success of its research and development programs; (2) the timely and successful completion of any additional financing; (3) the development of competitive therapies by other biotechnology and pharmaceutical companies; (4) the Company’s ability to manage growth of the organization; (5) the Company’s ability to protect its technology and products; and, ultimately (6) regulatory approval and successful commercialization and market acceptance of its product candidates.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of the Company and its controlled subsidiaries.

Unaudited Interim Financial Information

The accompanying interim condensed consolidated balance sheets as of September 30, 2025, condensed consolidated statements of operations and comprehensive (loss) income and stockholders’ deficit for the three and nine months ended September 30, 2025 and 2024, condensed consolidated statement of cash flows for the nine months ended September 30, 2025 and 2024, and the related note disclosures are unaudited. The balance sheet information as of December 31, 2024 is derived from the audited financial statements. These unaudited interim financial statements have been prepared in accordance with U.S. GAAP and, in management’s opinion, on a basis consistent with the audited financial statements and reflect all adjustments which only include normal recurring adjustments necessary for the fair presentation of the Company’s financial position as of September 30, 2025 and its results of operations and 6

Table of Contents comprehensive (loss) income for the three and nine months ended September 30, 2025 and September 30, 2024 and cash flows for the nine months ended September 30, 2025 and 2024. The results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or any other interim period.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. The Company’s most significant estimates relate to the research and development accruals, valuation of stock-based compensation, and the fair values of contingent consideration, forward purchase agreements, warrant liabilities, convertible notes, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.

Segment Reporting

The Company determined that it operates and manages its business as one operating segment, focused on the research and development of ABP-450. The Company’s chief operating decision maker (“CODM”) is the Company’s Chief Executive Officer, who reviews its consolidated operating results for the purpose of assessing liquidity needs, allocating resources and evaluating financial performance. Asset information, including monitoring of its cash and cash equivalents, provided to the CODM is consistent with those reported on the condensed consolidated balance sheets. The key measure of the Company’s single segment profit and loss that the CODM uses to allocate resources and assess performance is the Company’s operating (loss) income as reported on the condensed consolidated statement of operations and comprehensive (loss) income.

The table below shows a reconciliation of the Company’s net (loss) income, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under U.S. GAAP to the Company’s total consolidated net (loss) income as reported in the condensed consolidated statement of operations:

​

​	​	​	​	​	​	​	​	​	​	​	​
​	Three Months Ended					​	Nine Months Ended
​	September 30,					​	September 30,
​	2025			2024		​	2025			2024
​	​		​	​		​	​		​	​
Segment operating expenses:	​	​	​	​	​	​	​	​	​	​	​
Compensation and benefits	$	1,933	​	$	2,382	​	$	6,826	​	$	7,845
Professional and legal fees		450	​		1,030	​		2,838	​		4,748
Office and travel	​	233	​	​	408	​	​	746	​	​	1,206
Research and development		(86)	​		196	​		391	​		8,359
Total selling, general and administrative, and research and development		2,530	​		4,016	​		10,801	​		22,158
Change in fair value of contingent consideration	​	(37)	​	​	—	​	​	(3,509)	​	​	(97,464)
Total operating costs and expenses	​	2,493	​	​	4,016	​	​	7,292	​	​	(75,306)
(Loss) income from operations	​	(2,493)	​	​	(4,016)	​	​	(7,292)	​	​	75,306
Other segment items:			​			​			​
Change in fair value of convertible notes		(1,877)	​		(1,878)	​		(5,362)	​		(170)
Change in fair value of warrants		(236)	​		(377)	​		85,950	​		(15,376)
Loss on issuance of warrants	​	—	​	​	—	​	​	(75,644)	​	​	—
Loss on embedded forward purchase agreements and derivative liabilities, net	​	—	​		81	​	​	—	​		(19,931)
Other income, net		68	​		19	​		263	​		94
Total other segment items, net		(2,045)	​		(2,155)	​		5,207	​		(35,383)
(Loss) income before taxes		(4,538)	​		(6,171)	​		(2,085)	​		39,923
Income taxes		—	​		—	​		—	​		—
Segment net (loss) income	$	(4,538)	​	$	(6,171)	​	$	(2,085)	​	$	39,923

7

Table of Contents ​

Risk and Uncertainties

The Company is subject to risks common to early-stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients and significant competition.

The Company relies on Daewoong Pharmaceutical Co., Ltd. (“Daewoong”), a South Korean pharmaceutical manufacturer, as an exclusive and sole supplier to manufacture the Company’s source material for product candidates. Any termination or loss of significant rights, including exclusivity, under the Company’s license and supply agreement with Daewoong (the “Daewoong Agreement”) would materially and adversely affect the Company’s commercialization of its products. See Note 6 Commitments and Contingencies for a discussion of the Daewoong Agreement.

Property and Equipment

Property and equipment are carried at cost less accumulated depreciation and amortization. The cost of property and equipment is depreciated over the estimated useful lives of the respective assets. The Company’s furniture and fixtures are depreciated on a straight-line basis over a period of seven years. Equipment is depreciated over a useful life of five years. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the related lease term.

Property and equipment, net, as of September 30, 2025 and December 31, 2024 are as follows (in thousands):

​	​	​	​	​	​	​	​	​
​	​	September 30,		​	​	December 31,		​
​	****	2025		****	​	2024		​
Furniture and fixtures	​	$	199	​	​	$	199	​
Equipment	​		241	​	​		237	​
Leasehold improvements	​		66	​	​		66	​
Property and equipment	​		506	​	​		502	​
Accumulated depreciation	​		(325)	​	​		(267)	​
Property and equipment, net	​	$	181	​	​	$	235	​

​

Other Accrued Expenses

Other accrued expenses were as follows (in thousands):

​

​	​	​	​	​	​	​	​	​
​	****	​	September 30,	​	​	​	December 31,	​
​	​	​	2025	​	​	​	2024	​
Legal expenses	​	$	1,403	​	​	$	2,455	​
Excise tax liability	​	​	569	​	​	​	569	​
Operating lease liability - short term portion	​	​	247	​	​	​	121	​
Daewoong vial usage	​	​	228	​	​	​	—	​
Remaining other accrued expenses	​	​	185	​	​	​	455	​
Total other accrued expenses	​	$	2,632		​	$	3,600	​

​

Convertible Notes

The Company elected to account for its convertible notes at fair value at inception and at each subsequent reporting date. Subsequent changes in fair value are recorded as a component of non-operating (loss) income in the condensed consolidated statements of operations or as a component of other comprehensive (loss) income for changes related to instrument-specific credit risk. As a result of electing the fair value option, direct costs and fees related to the convertible notes are expensed as incurred. 8

Table of Contents

Contingent Consideration

The Company accounts for its contingent consideration as either equity-classified or liability-classified instruments based on an assessment of the Contingent Consideration Shares specific terms (as further defined in Note 5 Fair Value Measurements) and applicable authoritative guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and Derivatives and Hedging (“ASC 815”). Based on the appropriate guidance, the Company determined that the Contingent Consideration would be classified as a liability on the condensed consolidated balance sheets and remeasured at each reporting period with changes to fair value recorded to the condensed consolidated statements of operations and comprehensive (loss) income.

Forward Purchase Agreements

Based on the applicable guidance in ASC 480, ASC 815, Equity (“ASC 505”) and Staff Accounting Bulletin Topic 4.E, Receivables from Sale of Stock (“SAB 4E”), the Company had determined that each of its forward purchase agreements was a freestanding hybrid financial instrument comprising a subscription receivable and embedded features, which were bifurcated and accounted for separately as derivative instruments. The Company recorded the derivatives as liabilities and measured them at fair value each reporting period. For more information, see Note 5 Fair Value Measurement. Subsequent changes in the bifurcated derivatives were recorded in the condensed consolidated statements of operations and comprehensive (loss) income. The forward purchase agreements were terminated in March 2024, and the loss related to the termination was recorded to the condensed consolidated statement of operations and comprehensive (loss) income.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments and meet all of the requirements for equity classification, including whether the warrants are indexed to the Company’s own shares of common stock, among other conditions for equity classification. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter until settlement. Changes in the estimated fair value of the warrants are recognized in the condensed consolidated statements of operations and comprehensive (loss) income.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

Fair value measurements are based on a three-tiered valuation hierarchy, which is classified and disclosed by the Company in one of the three categories as follows:

·	Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
·	Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and
---	---
·	Level 3 — Prices or valuation techniques that require unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
---	---

9

Table of Contents The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

Leases

The Company determines whether a contract is, or contains, a lease at inception. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term using the Company’s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. The Company determines the lease term as the noncancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheets.

Research and Development Expenses

Research and development costs are expensed as incurred. Research and development expenses consist primarily of costs associated with the Company’s biosimilar analyses and clinical studies including clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of products used for biosimilar studies and clinical trials, consulting and internal and external costs associated with the Company’s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs. Additionally, research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses and an allocation of facility overhead expenses. Costs incurred in obtaining technology licenses are charged to acquired in-process research and development (“IPR&D”) if the technology licensed has not reached technological feasibility and has no alternative future use.

The Company accrues the expenses for its biosimilar and clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services. Payments made to outside service providers in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. The Company settled outstanding liabilities with its clinical research organization for the cervical dystonia and migraine programs and recorded a gain of $0.6 million in research and development expenses on the condensed consolidated statement of operations for the three and nine months ended September 30, 2025. Otherwise, there have been no material adjustments to the Company’s estimates for biosimilar and clinical trial expenses through September 30, 2025.

Stock-Based Compensation

The Company recognizes compensation expense for all share-based awards. The Company accounts for stock-based compensation as measured at grant date, based on the fair value of the award. The Company measures the fair value of awards granted using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including the estimated fair value of common stock, the expected volatility of the Company’s common stock, expected risk-free interest rate, and the option’s expected life. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.

The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed consolidated balance sheets and in selling, general and administrative or research and development expenses in the condensed consolidated statements of operations and comprehensive (loss) income. All stock-based compensation costs are recorded in the condensed consolidated statements of operations and comprehensive (loss) income based upon the underlying employee’s role within the Company. 10

Table of Contents

Net (loss) income Per Share

The Company only has one class of shares. Basic net (loss) income per share is computed by dividing the net (loss) income by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive shares of common stock. Diluted net (loss) income per share is computed by dividing the net (loss) income by the weighted-average shares of common stock and potentially dilutive securities outstanding during the period using the treasury stock and if-converted methods, unless their inclusion would have been anti-dilutive. For purposes of the diluted net loss per share calculation, warrants, convertible notes and common stock options were considered as potentially dilutive securities.

Since the company was in a loss position for three and nine months ended September 30, 2025 and three months ended September 30, 2024, basic net loss per share is the same as diluted net loss per share as the inclusion of all potentially dilutive shares of common stock was anti-dilutive, while the nine months ended September 30, 2024 contained dilutive securities.

Basic and diluted net (loss) income per share for three and nine months ended September 30, 2025 and 2024 were calculated as follows (in thousands, except share and per share amounts):

​

​	​	​	​
Three months ended September 30, 2025		​
Net loss		$	(4,538)
Weighted average shares of common stock outstanding, basic and diluted	​		11,634,946
Net loss per share, basic and diluted		$	(0.39)

​

​	​	​	​
Nine months ended September 30, 2025		​
Net loss	​	$	(2,085)
Weighted average shares of common stock outstanding, basic and diluted	​		8,931,566
Net loss per share, basic and diluted	​	$	(0.23)

​

​	​	​	​
Three months ended September 30, 2024		​
Net loss		$	(6,171)
Weighted average shares of common stock outstanding, basic and diluted	​		549,175
Net loss per share, basic and diluted		$	(11.24)

​

​	​	​	​
Nine months ended September 30, 2024		​	​
Net income	​	$	39,923
Weighted average shares of common stock outstanding, basic	​		535,693
Net income per share, basic	​	​	74.53
Weighted average shares of common stock outstanding, diluted	​	​	574,216
Net income per share, diluted	​	$	69.53

​

The following unweighted potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an anti-dilutive impact:

​

​	​	​	​	​	​	​	​	​
​	****	Three Months Ended			​	Nine Months Ended
​	​	September 30,			​	September 30,
​	​	2025	​	2024	​	2025	​	2024
Warrants	​	3,747,798	​	55,403	​	3,747,798	​	55,403
Contingent consideration	​	—	​	222,653	​	—	​	222,653
Common stock options and restricted stock units		461,962		124,585	​	461,962	​	86,061
Convertible notes	​	399,128	​	399,128	​	399,128	​	399,128
​		4,608,888		801,769	​	4,608,888	​	763,245

11

Table of Contents ​

Contingencies

The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible.

Recent Accounting Pronouncements

Accounting Pronouncements Not Yet Adopted

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its condensed consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which is intended to improve financial reporting by requiring disaggregated disclosure of certain costs and expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted, and may be applied on either a prospective or retrospective basis. The Company is currently evaluating the impact of this guidance on its condensed consolidated financial statements.

Note 3. Daewoong Convertible Notes

On March 19, 2024, the Company entered into a subscription agreement with Daewoong (the “Subscription Agreement”) relating to the sale and issuance by the Company of senior secured convertible notes (each, a “2024 Convertible Note” and together, the “2024 Convertible Notes”) in the principal amount of up to $15.0 million, which are convertible into shares of the Company’s common stock, subject to certain conditions and limitations set forth in each Convertible Note. Each Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. The Company will use the net proceeds from each Convertible Note to support the late-stage clinical development of its lead product candidate ABP-450 and for general working capital purposes. Pursuant to the terms of the Subscription Agreement, on March 24, 2024, the Company issued and sold to Daewoong one Convertible Note in the principal amount of $5.0 million, and on April 12, 2024, the Company issued and sold to Daewoong one Convertible Note in the principal amount of $10.0 million.

On March 19, 2024, the Company entered into a Fourth Amendment to the License Agreement (the “License Agreement Amendment”) with Daewoong, which amends that certain License and Supply Agreement, by and between the Company and Daewoong, dated December 20, 2019, as previously amended on July 29, 2022, January 8, 2023 and April 24, 2023 (the “License Agreement”). Pursuant to the terms of the License Agreement Amendment, the License Agreement will terminate if, over any six month period, (a) the Company ceases to commercialize ABP-450 in certain territories specified in the License Agreement and (b) the Company ceases to advance any clinical studies of ABP-450 in such territories. The License Agreement Amendment also provides that, in the event that the License Agreement is terminated for the foregoing reasons, Daewoong will have the right to purchase all Know-How (as defined in the License Agreement) related to ABP-450 for a price of $1.00 (the “Termination Purchase Right”). The Termination Purchase Right will terminate and expire upon Daewoong’s sale of 50% of its common stock, including common stock held by its affiliates and common stock that would be issued upon an Automatic Conversion or Optional Conversion (as defined in the Convertible Notes).

Due to certain embedded features within the convertible notes, the Company elected the fair value option to account for its convertible notes, including any paid-in-kind principal and interest, and the embedded features. For more information on fair value of convertible notes, see Note 5 Fair Value Measurements. 12

Table of Contents During the three and nine months ended September 30, 2025, the Company recognized $1.9 million and $5.4 million, respectively, of expense related to the increase in the fair value of the 2024 Daewoong Convertible Notes. During the three and nine months ended September 30, 2024, the Company recognized $1.9 million and $0.2 million, respectively, of expense related to the increase in the fair value of the 2024 Daewoong Convertible Notes. As of September 30, 2025 and December 31, 2024, the principal amount outstanding under the 2024 Daewoong Convertible Note was $15.0 million, with an estimated fair value inclusive of accrued interest of $17.1 million and $11.7 million, respectively.

Note 4. Public Offering

On January 6, 2025, the Company entered into an underwriting agreement with Aegis Capital Corp. (“Aegis” or the “Underwriter”) pursuant to which the Company agreed to sell and issue, in an underwritten public offering (the “Offering”) 555,571 Common Units, each consisting of (i) one (1) share of Common Stock, (ii) one (1) Series A Registered Common Warrant to purchase one (1) share of Common Stock per warrant (the “Series A Warrants”) at an exercise price of $45.00 (the “Exercise Price”) and (iii) one (1) Series B Registered Common Warrant to purchase one (1) share of Common Stock per warrant (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) at an Exercise Price of $45.00.

The Offering was made pursuant to that certain Registration Statement on Form S-3, as amended (File No. 333-281562), which was originally filed on August 15, 2024, and declared effective by the Securities and Exchange Commission on August 21, 2024, including the prospectus contained therein and a prospectus supplement dated January 6, 2025, filed with the Securities and Exchange Commission on January 7, 2025.

The closing of the Offering occurred on January 7, 2025. The Company received net proceeds of approximately $18.3 million from the Offering, after deducting the offering expenses payable by the Company, including the Underwriter’s fees and expenses. The Company intends to use the net proceeds from the Offering for general corporate purposes, including working capital.

The Series A Warrants were exercisable beginning on February 24, 2025, the date of approval by stockholders of the Company (the “Stockholder Approval Date” or the “Initial Exercise Date”), and will expire in February 2030, the sixty (60) month anniversary of the Initial Exercise Date. The Series B Warrants were exercisable beginning on the Initial Exercise Date and will expire in August 2027, on the thirty (30) month anniversary of the Initial Exercise Date.

Upon issuance, the Warrants have an initial exercise price of $45.00, which will be reset on the eleventh trading date after the Stockholder Approval Date (the “Reset Date”). Prior to the Stockholder Approval Date, the Warrants had a floor price of $20.23, and following stockholder approval, the Warrants will have a floor price of $8.06. The reset price would be the greater of (i) the lowest single trading day volume-weighted average price (“VWAP”) of the Company’s common stock during the reset period and (ii) the floor price, as defined in the agreement.

On February 24, 2025, the Company held a special stockholder meeting, at which stockholders voted, among other matters, to authorize stockholder approval of the Warrants within the context of the agreements for such Warrants. As such, as of February 24, 2025, the Warrants became exercisable. The stock price on the Reset Date was below the floor price following the Stockholder Approval Date, and as such, the exercise price was reset to $8.06.

Additionally, the Company granted Aegis a 45-day option to purchase additional shares of Common Stock and/or Warrants of (i) up to 15.0% of the number of shares of Common Stock sold in the offering, (ii) up to 15.0% of the number of Series A Warrants sold in the offering and (iii) up to 15.0% of the number of Series B Warrants sold in the offering. The purchase price per additional share of Common Stock is equal to the public offering price of one Common Unit (less $0.01 allocated to each full Warrant), less the underwriting discount. The purchase price per additional Warrant is $0.01. On January 7, 2025, Aegis exercised its over-allotment option with respect to 83,334 Series A Warrants and 83,334 Series B Warrants.

The holders of Series A Warrants can effect a cashless exercise if there is no effective registration statement at the time of exercise. The number of common shares to be issued would be calculated as VWAP minus exercise price of the Series A Warrants multiplied by the number Series A Warrants to be cashlessly exercised.

The holders of Series B Warrants may effect an alternative cashless exercise whether or not an effective registration statement is available for the issuance of shares. In such event, the number of shares to be issued would be calculated as the number of Series B Warrants to be cashlessly exercised multiplied by a factor of 3.0. 13

Table of Contents During the nine months ended September 30, 2025, certain holders of the Series B Warrants exercised 3,438,095 Series B Warrants, in accordance with the alternative cashless exercise provision in the Series B Warrants, resulting in the issuance of 10,314,285 shares of Common Stock of the Company. There were no exercises of Series B Warrants for the three months ended September 30, 2025. The fair value of the warrants exercised on the respective exercise dates for the nine months ended September 30, 2025 was $6.9 million. There were no Series A Warrants exercised during the three and nine months ended September 30, 2025. As of September 30, 2025, there were 3,565,245 and 127,150 units of Series A and Series B warrants outstanding, respectively.

On the date of issuance, the Company recognized a loss on issuance of Warrants of $75.6 million, which reflects the fair value of the warrants in excess of the proceeds received. For the nine months ended September 30, 2025, the Company recognized $58.3 million of income related to the change in fair value of the exercised Series B Warrants. For the three and nine months ended September 30, 2025, the Company recognized $(0.2) million and $18.6 million of (expense) income related to the change in fair value of the remaining outstanding Series A Warrants, respectively, and de minimus and $7.9 million of income related to the change in fair value of the remaining outstanding Series B Warrants, respectively. Refer to Note 5 Fair Value Measurements for additional information.

​

Note 5. Fair Value Measurements

The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The carrying value of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value because of the short-term nature of those instruments. The following are other financial assets and liabilities that are measured at fair value on a recurring basis.

Convertible Notes at Fair Value

Due to certain embedded features within the convertible notes, the Company elected the fair value option to account for its convertible notes, including any paid-in-kind principal and interest, and the embedded features. For more information on convertible notes, see Note 3 Daewoong Convertible Notes. The fair value of the convertible notes was determined based on Level 3 inputs using a scenario-based analysis that estimated the fair value of the convertible notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the noteholders, including various qualified financings, corporate transaction and dissolution scenarios. The significant unobservable input assumptions that can significantly change the fair value included (i) the weighted average cost of capital, (ii) the timing of payments, (iii) the discount for lack of marketability, and (iv) the probability of certain corporate scenarios. During the three months ended September 30, 2025 and 2024, the Company utilized discount rates ranging from 15% to 60%, reflecting changes in the Company’s risk profile, time-to-maturity probability, and key terms when modified to the convertible notes.

Termination of Forward Purchase Agreements

On March 18, 2024, the Company and ACM ARRT J LLC (“ACM”) entered into a termination agreement (the “ACM Termination Agreement”) terminating that certain Forward Purchase Agreement, dated June 29, 2023, by and among the Company and ACM (the “ACM FPA”). The ACM Termination Agreement provides that ACM will retain 43,056 previously issued shares of common stock held by ACM pursuant to the ACM FPA and its respective subscription agreement (the “ACM Retained Shares”). ACM did not pay any cash to the Company for the ACM Retained Shares and retained all portions of the Prepayment Amount associated with the ACM Retained Shares.

On March 18, 2024, the Company and Polar Multi-Strategy Fund (“Polar”) entered into a termination agreement (the “Polar Termination Agreement”) terminating that certain Forward Purchase Agreement, dated June 29, 2023, by and among the Company and Polar (the “Polar FPA”). The Polar Termination Agreement provides that Polar will retain 44,098 previously issued shares of common stock held by Polar pursuant to the Polar FPA and its respective subscription agreement (the “Polar Retained Shares”). Polar did not pay any cash to the Company for the Polar Retained Shares and retained all portions of the Prepayment Amount associated with the Polar Retained Shares.

As a result of the ACM Termination Agreement and Polar Termination Agreement, the Company recorded a charge to the condensed consolidated statement of operations of $20.3 million during the first quarter of 2024 to reverse the related subscription 14

Table of Contents receivable and derivative liability on the accompanying condensed consolidated balance sheet. Additionally, in the first quarter of 2024, the Company had recorded potential liquidated damages of $3.0 million related to ACM and Polar; however, since ACM and Polar each elected to remove its respective shares from the registration statement, the Company released the liability from the condensed consolidated balance sheet during the second quarter of 2024.

In connection with the negotiation of the Forward Purchase Agreements (and FPA Termination Agreements) and related subscription agreements, J.V.B. Financial Group, LLC, acting through its Cohen & Company Capital Markets division (“CCM”), provided certain consulting services, initially to Priveterra and subsequently to AEON, pursuant to an engagement letter, by and between the Company and CCM, dated July 27, 2023 and amended July 1, 2024 (the “CCM Engagement Letter”). On July 5, 2024, pursuant to the CCM Engagement Letter, the Company issued 5,556 shares of the Company’s common stock to CCM.

Contingent Consideration and Contingent Founder Shares

As part of the Business Combination Agreement, certain Founder Shares and Participating Stockholders shares (together, “Contingent Consideration Shares”), as further discussed below, contain certain contingent provisions.

On April 27, 2023, concurrently with the amendment of the Business Combination Agreement, Priveterra amended the Sponsor Support Agreement to include restriction and forfeiture provisions related to the Founder Shares. In addition, following the Closing, certain AEON stockholders will be issued up to 222,653 additional shares of common stock.

Pursuant to the terms of the amended Sponsor Support Agreement, effective immediately after the Closing, 50% of the Founder Shares (i.e., 47,921 Founder Shares) (the “Contingent Founder Shares”) were unvested and subject to the restrictions and forfeiture provisions set forth in this Sponsor Support Agreement, of which 13,980 of such Contingent Founder Shares were forfeited on June 30, 2025 as the result of a vesting event not occurring. The remaining 50% of the Founder Shares were not subject to such restrictions and forfeiture provisions. The remaining Contingent Founder Shares shall vest, and shall become free of the provisions as follows:

●	13,890 of the Contingent Founder Shares shall vest upon the achievement of the conditions for the issuance of the CD BLA Contingent Consideration Shares (as defined below) on or prior to the CD BLA Outside Date; and
●	20,141 of the Contingent Founder Shares shall vest upon the earlier of (x) the achievement of the conditions for the issuance of the Episodic Migraine Contingent Consideration Shares (as defined below) on or before the Episodic Migraine Outside Date (as defined below) and (y) the achievement of the conditions for the issuance of the Chronic Migraine Contingent Consideration Shares (as defined below) on or before the Chronic Migraine Outside Date (as defined below).
---	---

The Priveterra Sponsor, LLC (the “Sponsor”) has agreed not to vote the Contingent Founder Shares during any period of time that such Contingent Founder Shares are subject to vesting.

Following the Closing, in addition to the consideration received at the Closing and as part of the overall consideration paid in connection with the Merger, certain holders of common stock in Old AEON may be issued a portion of up to 208,657 additional shares of common stock, subject to the occurrence of the following milestones:

●	55,659 shares of common stock, in the aggregate, if, on or before November 30, 2026 (as it may be extended, the “CD BLA Outside Date”), the Company shall have received from the FDA acceptance for review of the BLA submitted by the Company for the treatment of cervical dystonia (such 55,659 shares of common stock, the “CD BLA Contingent Consideration Shares”);
●	55,659 shares of common stock, in the aggregate, if, on or before June 30, 2029 (as it may be extended, the “Episodic Migraine Outside Date”), the Company shall have received from the FDA acceptance for review of the BLA submitted by the Company for the treatment of episodic migraine (such 55,659 shares of common stock, the “Episodic Migraine Contingent Consideration Shares”); provided that in the event the satisfaction of the conditions for the issuance of the Episodic Migraine Contingent Consideration Shares occurs prior to the satisfaction of the conditions for the issuance of the Chronic Migraine Contingent Consideration Shares, then the number of Episodic Migraine Contingent Consideration Shares shall be increased to 152,998 shares of common stock; and
---	---

15

Table of Contents

●	97,339 shares of common stock, in the aggregate, if, on or before June 30, 2028, the Company shall have received from the FDA acceptance for review of the BLA submitted by AEON for the treatment of chronic migraine (such 97,339 shares of common stock, the “Chronic Migraine Contingent Consideration Shares”); provided that in the event that the number of Episodic Migraine Contingent Consideration Shares is increased to 152,998, then the number of Chronic Migraine Contingent Consideration Shares shall be decreased to zero and no Contingent Consideration Shares will be issued in connection with the satisfaction of the conditions to the issuance of the Chronic Migraine Contingent Consideration Shares.
●	In the event that the Company licenses any of its products (except in connection with migraine or cervical dystonia indications) to a third-party licensor for distribution in the U.S. market (a “Qualifying License”) prior to the satisfaction of (x) the conditions for the issuance of the Episodic Migraine Contingent Consideration Shares and (y) the conditions for the issuance of the Chronic Migraine Contingent Consideration Shares, then upon the entry of AEON into such Qualifying License, 27,992 shares of common stock shall become due and payable to Participating Stockholders and the number of Episodic Migraine Contingent Consideration Shares and (A) the number of Episodic Migraine Contingent Consideration Shares shall be reduced by 13,996 or by 27,992 and (B) the number of Chronic Migraine Contingent Consideration Shares shall be reduced by 13,996, but not below zero.
---	---

The Company classifies the Contingent Consideration as a liability on the condensed consolidated balance sheets and remeasures at each reporting period with changes to fair value recorded to the condensed consolidated statements of operations and comprehensive (loss) income.

The Company utilized the Probability-Weighted Expected Return Method (PWERM) model to value the contingent consideration based on earnout milestones, probability of forfeiture and success scenarios. For the three and nine months ended September 30, 2025 and September 30, 2024, the Company recognized $37 thousand, $3.5 million, $0 and $97.5 million of income, respectively, related to the change in fair value of contingent consideration on the condensed consolidated statements of operations and comprehensive (loss) income, and relates to the change in probabilities of achieving certain scenarios prior to and following the clinical results released in the second quarter of 2024 and changes in the Company’s stock price during the period. As of September 30, 2025 and December 31, 2024, the contingent consideration liability was $32 thousand and $3.5 million, respectively.

Warrants

Public and Private Placement Warrants related to the Closing

Upon the Closing, 201,112 warrants, consisting of 127,788 public warrants sold in Priveterra’s initial public offering and 73,334 warrants issued in a concurrent private placement, were outstanding. The terms of the warrants are governed by a Warrant Agreement dated February 8, 2021 between the Company (then known as Priveterra Acquisition Corp.) and Continental Stock Transfer & Trust Company (the “Warrant Agreement”).

Public warrants related to the Closing

Each whole public warrant entitles the holder to purchase one share of the Company’s common stock at a price of $828.00 per share. The public warrants became exercisable 30 days after the completion of the Merger, and will expire at 5:00 p.m., New York City time, on July 21, 2028, the five-year anniversary of the completion of the Merger, or earlier upon redemption or liquidation. Warrant holders may, until such time as there is an effective registration statement and during any period when the Company has failed to maintain an effective registration statement covering the shares of the Company’s common stock issuable upon exercise of the warrants, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exception. When exercised on a cashless basis, the number of shares received per warrant is capped at 1.0.

The Company may call the public warrants for redemption for cash:

●	in whole and not in part;
●	at a price of $0.72 per warrant;
---	---
●	upon not less than 30 days’ prior written notice of redemption to each warrant holder (the “30-day redemption period”);
---	---

16

Table of Contents

●	if, and only if, there is an effective registration statement under the Securities Act of 1933 covering the issuance of the shares of common stock issuable upon exercise of the warrants, and a current prospectus relating thereto, available through the 30-day redemption period; and
●	if, and only if, the closing price of the Company's common stock equals or exceeds $1,296.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company sends to the notice of redemption to the warrant holders.
---	---

The Company may also call the public warrants for redemption:

●	in whole and not in part;
●	at $7.20 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares to be determined by reference to a table in the Warrant Agreement, based on the redemption date and the “fair market value” (as defined in the Warrant Agreement) of common stock except as otherwise described below; and
---	---
●	if, and only if, the closing price of the Company’s common stock equals or exceeds $720.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company sends to the notice of redemption to the warrant holders.
---	---

On March 29, 2024, the Company delivered notice of redemptions to warrant holders with a redemption date of April 29, 2024 for cashless redemptions of the Company’s outstanding public warrants. The number of shares of common stock that each exercising warrant holder received by virtue of the cashless exercise (instead of paying the $11.50 per public warrant cash exercise price) was calculated in accordance with the terms of the Warrant Agreement. Any remaining unexercised public warrants on the redemption date were cancelled and the public warrant holders received the redemption price of $0.10 for each public warrant. The Company paid $21 thousand in April 2024 related to the cancellation of the remaining 2,881 public warrants on the redemption date.

Private placement warrants related to the Closing

Each private placement warrant was identical to the public warrants initially sold by Priveterra in the IPO, except that the private placement warrants, so long as they are held by the Sponsor or its permitted transferees, (i) will not be redeemable by the Company and (ii) may be exercised by the holders on a cashless basis.

Warrant exercises for Warrants related to the Closing

There were no warrants related to the Closing exercised during the three and nine months ended September 30, 2025 and the three months ended September 30, 2024. During the nine months ended September 30, 2024, there were 142,828 warrants exercised on a cashless basis for 27,310 shares of common stock, with an impact to additional paid in capital of $15.0 million. A summary of activity for the Company’s issued and outstanding public and private warrants related to the Closing for the nine months ended September 30, 2025 and 2024 is as follows:

​ 17

Table of Contents

​	​	​	​	​
​	​	Public	​	Private
​	​	​	​	​
Issued and Outstanding, January 1, 2025	​	—	​	55,403
Number of warrants issued	​	—	​	—
Number of warrants exercised	​	—	​	—
Number of warrants cancelled	​	—	​	—
Issued and Outstanding, September 30, 2025	​	—	​	55,403
​	​	​	​	​
Issued and Outstanding, January 1, 2024	​	127,778	​	73,334
Number of warrants exercised	​	(124,897)	​	(17,931)
Number of warrants cancelled	​	(2,881)	​	—
Issued and Outstanding, September 30, 2024	​	—	​	55,403

​

The private warrants are accounted for as a liability with changes in the fair value recorded to the condensed consolidated statement of operations. The Company utilized the Black-Scholes option pricing model (Level 3), which requires the input of subjective assumptions, including the Company’s stock price, expected volatility of the Company’s common stock, expected risk-free interest rate, and the option’s expected remaining life. The fair value of the warrants at September 30, 2025 and December 31, 2024 were de minimus and $1.2 million, respectively. For the three and nine months ended September 30, 2025 and 2024, the Company recorded de minimus, $1.2 million, $(0.4) million, and $(15.4) million, respectively, of income (expense) related to the change in fair value of the warrants related to the Closing.

Series A and Series B Warrants

The measurement of fair value for the Series A and Series B warrants were determined utilizing a Monte-Carlo simulation considering all relevant assumptions at the date of issuance of January 7, 2025 and at September 30, 2025. The fair value on grant date was recorded as a liability on the condensed consolidated balance sheets and changes in fair value will be recognized at each reporting period on the condensed consolidated statement of operations.

The table below summarizes the significant assumptions:

​

​	​	​	​	​	​	​	​	​	​	​	​
​	September 30,					​	January 7
​	2025					​	2025
​	​	Series A	​	​	Series B	​	​	Series A	​	​	Series B
​	​	(Level 3)	​	​	(Level 3)	​	​	(Level 3)	​	​	(Level 3)
Stock Price	$	0.81	​	$	0.81	​	$	15.91	​	$	15.91
Exercise Price	​	8.06	​	​	8.06	​	​	45.00	​	​	45.00
Expected volatility		151.00%	​	​	203.00%		​	99.00%	​	​	130.00%
Risk-free interest rate		3.70%	​	​	3.60%		​	4.36%	​	​	4.22%
Expected life (in years)		4.27	​	​	1.77		​	5.00	​	​	2.50
Expected dividend yield		—	​	​	—		​	—	​	​	—

​

The grant date fair values for these warrants were $94.0 million, comprised of $20.7 million and $73.3 million for Series A and Series B Warrants, respectively, on January 7, 2025 and was recorded as a liability as of the grant date due to certain exercise price adjustment provisions occurring in connection with future events. Proceeds were allocated to the warrant liability based on the fair value as of grant date of the warrants of $94.0 million. As the fair value of the warrants issued were greater than the proceeds received, the Company recognized a loss on issuance of common shares and the warrants of $75.6 million.

A summary of activity for the Company’s issued and outstanding Series A and Series B warrants for the nine months ended September 30, 2025 is as follows:

​

​	​	​	​	​
​	​	Series A	​	Series B
​	​	​	​	​
Issued and Outstanding, January 1, 2025	​	—	​	—
Number of warrants issued	​	3,565,245	​	3,565,245
Number of warrants exercised	​	—	​	(3,438,095)
Issued and Outstanding, September 30, 2025	​	3,565,245	​	127,150

18

Table of Contents ​

​

Summary of Recurring Fair Value Measurements

The following details the Company’s recurring measurements for assets and liabilities at fair value (in thousands):

​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	​	Convertible Notes	​	​	Warrant Liabilities	​	​	Contingent Consideration	​	​	Embedded Forward Purchase Agreement and Make Whole Derivative
​	​	​	(Level 3)	​	​	(Level 3)	​	​	(Level 3)	​	​	(Level 3)
​	​	​	​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​	​	​	​
Balance, January 1, 2025	​	$	11,689	​	$	1,187	​	$	3,541	​	$	—
Issuance of convertible notes	​	​	—	​	​	—	​	​	—	​	​	—
Issuance of warrants	​	​	—	​	​	93,986	​	​	—	​	​	—
Change in fair value	​	​	5,362	​	​	(85,950)	​	​	(3,509)	​	​	—
Warrant cashless exercise	​	​	—	​	​	(6,885)	​	​	—	​	​	—
Termination of forward purchase agreements	​	​	—	​	​	—	​	​	—	​	​	—
Balance, September 30, 2025	​	$	17,051	​	$	2,338	​	$	32	​	$	—
​	​	​	​	​	​	​	​	​	​	​	​	​
Balance, January 1, 2024	​	$	—	​	$	1,447	​	$	104,350	​	$	41,043
Issuance of convertible notes	​	​	15,000	​	​	—	​	​	—	​	​	—
Change in fair value	​	​	170	​	​	15,376	​	​	(97,464)	​	​	(399)
Warrant cashless exercise	​	​	—	​	​	(14,979)	​	​	—	​	​	—
Termination of forward purchase agreements	​	​	—	​	​	—	​	​	—	​	​	(40,380)
Balance, September 30, 2024	​	$	15,170	​	$	1,844	​	$	6,886	​	$	264

​

​

​

​

Note 6. Commitments and Contingencies

Operating Leases

In December 2021, the Company entered into a three-year non-cancellable lease for office space. The lease was extended for an additional five years in March 2024. The lease does not include variable or contingent lease payments. An operating lease asset and liability are recognized based on the present value of the remaining lease payments discounted using the Company’s incremental borrowing rate. Lease expense is recognized on a straight-line basis over the lease term. 19

Table of Contents The following table summarizes supplemental balance sheet information related to the operating lease as of September 30, 2025 (in thousands):

​

​	​	​	​	​
Minimum lease payments by fiscal year		​		​
2025 (Remaining)	​	$	72	​
2026	​		297	​
2027	​	​	307	​
2028	​	​	318	​
2029	​	​	329	​
Thereafter	​	​	—	​
Total future minimum lease payments	​		1,323	​
Less: Imputed interest	​		(119)	​
Present value of lease payments	​		1,204	​
Less: Current portion (included in other accrued expenses)	​		(247)	​
Noncurrent operating lease liability	​	$	957	​
Operating lease right-of-use asset	​	$	1,112	​
Remaining lease term in years	​		4.3	​
Discount rate	​		4.3	%

​

The following table summarizes supplemental disclosures of operating cost and cash flow information related to operating leases for three and nine months ended September 30, 2025 and 2024 (in thousands).

​	​	​	​	​	​	​	​	​	​	​	​
​	Three Months Ended					****	Nine Months Ended
​	September 30,					​	September 30,
​	2025		​	2024		​	2025		​	2024
Cost of operating leases	$	72	​	$	72	​	$	217	​	​	188
Cash paid for operating leases		72	​		80	​	​	103	​	​	239

​

Daewoong License and Supply Agreement

On December 20, 2019, the Company entered into the Daewoong Agreement, pursuant to which Daewoong agreed to manufacture and supply ABP-450 and grant the Company an exclusive license for therapeutic indications to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit ABP-450 in the United States, the European Union, the United Kingdom, Canada, Australia, Russia, the Commonwealth of Independent States and South Africa (collectively the “covered territories”).

Daewoong supplies the Company with ABP-450 at an agreed-upon transfer price, with no milestone or royalty payments and no minimum purchase requirements. Daewoong is responsible for all costs related to the manufacturing of ABP-450, including costs related to the operation and upkeep of its manufacturing facility, and the Company is responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of ABP-450. The Company’s exclusivity is subject to its exercise of commercially reasonable efforts to: (i) achieve all regulatory approvals necessary for ABP-450 to be marketed in the territory for therapeutic indications and (ii) commercialize ABP-450 in the territory for therapeutic indications. During the term of the Daewoong Agreement, the Company cannot purchase, sell or distribute any competing products in a covered territory or sell ABP-450 outside a covered territory.

The initial term of the Daewoong Agreement is from December 20, 2019 to the later of (i) the fifth anniversary of approval from the relevant governmental authority necessary to market and sell ABP-450 or (ii) December 20, 2029, and automatically renews for unlimited additional three-year terms, provided the Daewoong Agreement is not earlier terminated. The Daewoong Agreement will terminate upon written notice by either the Company or Daewoong upon a continuing default that remains uncured within 90 days (or 30 days for a payment default) by the other party, or without notice upon the bankruptcy or insolvency of the Company.

The Company has recorded $0.2 million and $0 as a liability in accrued expenses on the condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024 for ABP-450 supplies, respectively. 20

Table of Contents

Legal Proceedings

The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. Other than as described below, the Company is not subject to any currently pending legal matters or claims that would have a material adverse effect on its accompanying financial position, results of operations or cash flows.

On September 18, 2023, Odeon Capital Group LLC (“Odeon”) filed a lawsuit against the Company in the Supreme Court of the State of New York, alleging that the Company failed to pay Odeon’s deferred underwriting fee of $1.25 million, and seeking monetary damages for the full amount of its claimed underwriting fee, punitive damages, attorneys’ fees and other amounts, totaling approximately $1.7 million, which was recorded in other accrued expenses on the condensed consolidated balance sheets as of December 31, 2024. On October 31, 2025, the Company entered into a settlement agreement with Odeon to settle the lawsuit in exchange for $1.0 million in cash, $0.3 million shares of common stock and 125,000 warrants to purchase shares of common stock with an exercise price of $2.00 and a three-year term. The Company recorded a gain on settlement of $0.4 million to selling, general and administrative expenses on the condensed consolidated statement of operations for the three and nine months ended September 30, 2025.

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. See Note 2 Summary of Significant Accounting Policies for additional information.

Note 7. Common Stock

On February 24, 2025, the Company held a special stockholder meeting, at which stockholders voted, among other matters, to amend the Company’s Certificate of Incorporation, as amended and restated, to increase the number of authorized common stock from 500,000,000 to 1,040,000,000 shares of common stock at par value of $0.0001 per share. The holders of common stock are entitled to receive dividends whenever funds are legally available, when and if declared by the Company’s Board of Directors. As of September 30, 2025, there have been no cash dividend declared to date. Each share of common stock is entitled to one vote.

Common Stock Reserved

The table below summarizes the Company’s reserved common stock for further issuance as of September 30, 2025 and December 31, 2024:

​

​	​	​	​	​	​
​	****	September 30,	​	December 31,	​
​	​	2025	​	2024	​
​	​	​	​	​	​
Stock options issued and outstanding		158,005		98,971	​
Restricted stock units (unvested)		303,957		25,613	​
Shares available for future issuance under the stock incentive plans and employee stock purchase plan	​	720,800		25,818	​
Warrants	​	3,747,798		55,403	​
Contingent consideration	​	208,657		222,653	​
Convertible notes	​	399,128	​	399,128	​
Total common stock reserved		5,538,345		827,586	​

​ 21

Table of Contents 2023 Employee Stock Purchase Plan (“ESPP”)

The 2023 Employee Stock Purchase Plan assists eligible employees in acquiring a stock ownership interest of the Company’s common stock in consideration of the participating employees’ continued services. Eligible employees will be entitled to purchase, by means of payroll deductions, limited amounts of the Company’s common stock at a discount during periodic offering periods. There were 6,780 shares initially reserved for issuance under the 2023 ESPP, which shall automatically increase on January 1 of each calendar year beginning and including January 1, 2024 and ending on and including January 1, 2033, by an amount equal to the lesser of (i) 1.0% of the total number of shares of common stock issued and outstanding on January 1 of the year in which such increase is to occur, or (ii) such smaller number of shares of common stock as may be established by the Board of Directors. As of September 30, 2025, there were 19,419 shares available for issuance. There have been no shares issued under the 2023 ESPP.

​

​

Note 8. Share-based Compensation ****

2019 Incentive Award Plan

​

The following table summarizes stock option activity under the 2019 Award Plan:

​

​	​	​	​	​	​	​
​	****	​	****	Weighted		​
​	​	​	​	Average		​
​	​	Number of	​	Exercise		​
​	​	Shares	​	Price		​
Outstanding, January 1, 2025	​	47,955	​	$	720.00	​
Options granted		—	​	​	—	​
Options forfeited		—	​	​	—	​
Outstanding, September 30, 2025		47,955	​	$	720.00	​
Exercisable, September 30, 2025		44,595	​	$	720.00	​

​

As of September 30, 2025 and December 31, 2024, the weighted average remaining contractual life of options outstanding and options exercisable was 5.3 years and 6.0 years, respectively.

During the three and nine months ended September 30, 2025 and 2024, the Company recognized $0.3 million and $1.3 million, $0.7 million and $2.3 million, respectively, of share-based compensation expense related to stock options granted.

As of September 30, 2025 and December 31, 2024, total unrecognized compensation expense related to nonvested stock options was $0.5 million and $1.8 million, respectively, which is expected to be recognized over the weighted-average remaining requisite service period of 1 month and 4 months, respectively.

The following table summarizes restricted stock units activity under the 2019 Award Plan:

​

​	​	​	​	​	​	​
​	****	​	****	Weighted		​
​	​	​	​	Average		​
​	​	Number of	​	Grant Date		​
​	​	Shares	​	Fair Value		​
Outstanding, January 1, 2025		11,398	​	$	780.48	​
Granted		—	​		—	​
Vested		(1,639)	​	​	—	​
Forfeited	​	—	​	​	—	​
Outstanding, September 30, 2025		9,759	​	$	780.48	​

​

During three and nine months ended September 30, 2025 and 2024, the Company recognized $0.3 million, $1.0 million, $0.3 million and $1.1 million, respectively, of share-based compensation expense related to restricted stock units granted, excluding restricted stock units with earnout vesting criteria. For the restricted stock units with earnout vesting criteria, the Company recognized $0.1 million and $0.5 million for the three and nine months ended September 30, 2024. As of September 30, 2025, the Company determined that the earnout vesting criteria was no longer probable, as such, the Company reversed $1.0 million of share-based compensation expense related to the restricted stock units with earnout criteria during the three and nine months ended September 30, 2025. 22

Table of Contents As of September 30, 2025 and December 31, 2024, total unrecognized compensation expense related to nonvested restricted stock units was $2.0 million and $3.0 million, respectively, which is expected to be recognized over the weighted-average remaining requisite service period of 14 months and 21 months, respectively. The unrecognized compensation expense with the earnout criteria as of September 30, 2025 and December 31, 2024 of $5.1 million and $4.3 million, respectively, will be recognized when the milestones are determined to be probable over the RSUs vesting term, calculated as the period from the date the milestone was determined to be probable and the expected achievement date of the milestone.

2023 Incentive Award Plan

As of September 30, 2025 there were 40,398 shares of common stock available for issuance under the Company’s 2023 Incentive Award Plan (the “2023 Award Plan”). The following table summarizes stock options activity under the 2023 Award Plan:

​

​	​	​	​	​	​	​
​	****	​	****	Weighted		​
​	​	​	​	Average		​
​	​	Number of	​	Exercise		​
​	​	Shares	​	Price		​
​	​	​	​	​	​	​
Outstanding, January 1, 2025		51,016	​	$	242.14	​
Options granted		—	​	​	—	​
Options forfeited		—	​	​	—	​
Outstanding, September 30, 2025		51,016	​	$	242.14	​
Exercisable, September 30, 2025		32,426	​	$	—	​

​

The weighted average remaining contractual life of options outstanding and options exercisable as of September 30, 2025 and December 31, 2024 was 8.7 years and 9.5 years, respectively.

During the three and nine months ended September 30, 2025 and 2024, the Company recognized $0.6 million, $1.9 million, $0.5 million and $1.0 million respectively, of share-based compensation expense related to stock options granted. As of September 30, 2025 and December 31, 2024, total unrecognized compensation expense related to nonvested stock options was $3.4 million and $5.3 million, respectively, which is expected to be recognized over the weighted-average remaining requisite service period of 10 months and 19 months, respectively.

The following table summarizes restricted stock units activity under the 2023 Award Plan:

​

​	​	​	​	​	​
​	****	​	****	Weighted
​	​	​	​	Average
​	​	Number of	​	Grant Date
​	​	Shares	​	Fair Value
​	​	​	​	​	​
Outstanding, January 1, 2025		14,215	​	$	60.05
Granted		—	​	​	—
Vested		—	​		—
Forfeited		—	​	​	—
Outstanding, September 30, 2025		14,215	​	$	60.05

​

During the three and nine months ended September 30, 2025, the Company recognized $0.1 million and $0.3 million, and de minimus stock-based compensation expenses for the three and nine months ended September 30, 2024.

As of September 30, 2025 and December 31, 2024, total unrecognized compensation expense related to nonvested restricted stock units was $0.4 million and $0.7 million, respectively, which is expected to be recognized over the weighted-average remaining requisite service period of 11 and 20 months, respectively.

In May 2025, under the 2023 Award Plan, the Board approved cash-settled restricted stock units, which are share-based awards granted to employees and directors over a vesting period that entitle the grantee to receive the cash equivalent to the value of a share of the Company’s common stock upon each vesting anniversary. 23

Table of Contents During the three and nine months ended September 30, 2025, there were 5,288,059 cash-settled restricted stock units granted with weighted-average grant date fair value of $0.81 with one, three, and four-year vesting, subject to continued service through the applicable vesting date. There were no units vested as of September 30, 2025.

The Company has elected to account for cash-settled restricted stock units in accordance with ASC 718. The Company will recognize compensation expense on the condensed consolidated statement of operations and record the associated liability to accrued compensation on the condensed consolidated balance sheets using straight-line method over the service period. Additionally, changes in fair value of the awards will be recorded to operating costs on the condensed consolidated statement of operations at each reporting date until settlement, reflecting changes in the underlying stock price.

During the three and nine months ended September 30, 2025, the Company recognized $0.6 million and $0.7 million of share-based compensation expense related to cash-settled restricted stock units granted. As of September 30, 2025, total unrecognized compensation expense related to nonvested cash-settled restricted stock units was $3.6 million, which is expected to be recognized over the weighted-average remaining requisite service period of 34 months. As of September 30, 2025, the liability related to cash-settled restricted stock units was $0.7 million in accrued compensation on the condensed consolidated balance sheet.

2025 Employee Inducement Incentive Award Plan

Effective April 19, 2025, the Board adopted the 2025 Employment Inducement Incentive Award Plan (the “Inducement Plan”) and, subject to the adjustment provisions of the Inducement Plan, reserved 1,000,000 shares of the Company’s Class A common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan provides for the grant of equity-based awards, including non-statutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance stock units, and its terms are substantially similar to the 2023 Award Plan. In accordance with the NYSE American Company Guide, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals’ bona fide period of non-employment with the Company), as an inducement material to the individuals’ entry into employment with the Company or being rehired following a bona fide period of interruption of employment by the Company. The Inducement Plan was adopted without stockholder approval pursuant to the applicable provisions of the NYSE American Company Guide. As of September 30, 2025, there were 660,983 shares of common stock available for issuance under the Inducement Plan.

For the nine months ended September 30, 2025 there were 59,034 stock options issued, with weighted average exercise price of $0.41. The weighted average fair value of options granted as of September 30, 2025 was $0.37. The weighted average remaining contractual life of options outstanding and options exercisable as of September 30, 2025 was 9.6 years. During the three and nine months ended September 30, 2025, the Company recognized de minimus amounts of share-based compensation expense related to stock options granted. As of September 30, 2025, total unrecognized compensation expense related to nonvested stock options was $20 thousand, which is expected to be recognized over the weighted-average remaining requisite service period of 43 months.

For the nine months ended September 30, 2025, there were 279,983 restricted stock units issued, with weighted averaged grant date fair value of $0.49. During the three and nine months ended September 30, 2025, the Company recognized de minimus amounts of share-based compensation expense related to restricted stock units granted. As of September 30, 2025, total unrecognized compensation expense related to nonvested restricted stock units was $0.1 million, which is expected to be recognized over the weighted-average remaining requisite service period of 43 months.

Share-based Compensation Expense and Valuation Information

The Company accounts for the measurement and recognition of compensation expense for all share-based awards based on the estimated fair value of the awards. The fair value of share-based awards is amortized on a straight-line basis over the requisite service period. The Company records share-based compensation expense net of actual forfeitures.

During the three and nine months ended September 30, 2025 and 2024, the Company recognized $1.0 million, $4.4 million $1.6 million and $4.9 million, respectively, of share-based compensation expense, of which $0.6 million, $3.3 million, $1.2 million, and $3.7 million, respectively, were in selling, general and administrative expenses, and $0.3 million and $1.1 million and $0.4 million and $1.3 million respectively, were in research and development expenses in the accompanying condensed consolidated statements of operations and comprehensive (loss) income. 24

Table of Contents The fair value of stock options granted under the Award Plan was estimated using the following assumptions:

​

​	​	​	​	​	​
​	​	Nine Months Ended			​
​	​	September 30,			​
​	​	2025	​	2024	​
​	​	​	​	​	​
Expected volatility	​	123%		47% – 87%	​
Risk-free interest rate	​	3.9%		3.7% – 4.3%	​
Expected life (in years)	​	6.25		5.27 – 6.25	​
Expected dividend yield	​	—		—	​

​

​

Note 9. Subsequent Events

The Company has further evaluated subsequent events for recognition and remeasurement purposes as of and for the three and nine months ended September 30, 2025. After review and evaluation, management has concluded that there were no material subsequent events as of the date of the issuance of the financial statements, except as described below.

On October 31, 2025, the Company entered into a settlement agreement with Odeon to settle a lawsuit filed against the Company in exchange for $1.0 million in cash, $0.3 million shares of common stock and 125,000 warrants with exercise price of $2.00 and a three year term. The Company recorded a gain on settlement of $0.4 million to selling, general and administrative expenses on the condensed consolidated statement of operations for the three and nine months ended September 30, 2025.

On November 12, 2025, the Company entered into a securities purchase agreement for a private placement (“PIPE”) financing for: (i) the sale of 6,581,829 shares of the Company’s Class A common stock (or pre-funded warrants in lieu of shares) at a price per share of $0.9116, for gross proceeds of $6 million; (ii) five-year warrants to purchase up to 6,581,829 shares of Class A common stock at an exercise price of $1.094 per share (the “PIPE Warrants”); and (iii) the investors’ rights to receive anti-dilutive warrants following the exchange of the Daewoong 2024 Convertible Notes, for a number of shares not to exceed 6,581,829 shares (the “anti-dilutive Warrants”). The PIPE financing will close in two stages. The first closing is expected to occur in November 2025, subject to the satisfaction of customary closing conditions, and result in $1.79 million in gross proceeds to the Company. The second closing will be subject to stockholder approval, the closing of the exchange of the Daewoong 2024 Convertible Notes, and other customary closing conditions. The PIPE Warrants and anti-dilutive Warrants will be issued only at the second closing. The Company plans to use net proceeds to further advance analytical work for its ABP-450 biosimilar program, and for general corporate purposes.

On November 13, 2025, the Company announced that it has entered into a binding term sheet with Daewoong contemplating the exchange of the 2024 Convertible Notes of $15.0 million in principal plus accrued interest for approximately 23,103,694 shares of Class A common stock (or pre-funded warrants in lieu of shares), a $1.5 million new convertible note due 2030 with interest rate of 15.79%, and approximately 8 million cash-exercise warrants on the same term as the PIPE Warrants (the “Exchange”). The parties expect to enter into definitive documentation for the Exchange in the coming weeks following execution of definitive documentation. The consummation of the Exchange will be subject to stockholder approval.

​

​ 25

Table of Contents Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of financial condition and results of operations should be read together with the consolidated financial statements and the related notes and other financial information included elsewhere in this Report. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the sections of this Report captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements”, actual results may differ materially from those anticipated in these forward-looking statements. Unless the context otherwise requires, references to “we”, “us”, “our,” “AEON” and “the Company” refer to the business and operations of AEON Biopharma, Inc. and its consolidated subsidiaries.

Company Overview

We are a biopharmaceutical company seeking accelerated and full-label United States (“U.S.”) market entry by developing our ABP-450 as a BOTOXÒ biosimilar for debilitating medical conditions. We plan to develop and seek regulatory approval of ABP-450 as a biosimilar product in the U.S. through submission of a Biologics License Application, (“BLA”), under Section 351(k) of the Public Health Service Act, (“Section 351(k) BLA”) with the ultimate goal of addressing the global therapeutic botulinum toxin market, which we estimate to be at least $3.3 billion based on AbbVie’s reported global revenues for its therapeutic Botox segment for the fiscal year ended 2024. ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current Good Manufacturing Practice (“cGMP”), in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency. ABP-450 is the same botulinum toxin complex that is currently approved as a biosimilar in Mexico, India and Philippines and, in the U.S., is approved to provide temporary improvement in the appearance of moderate to severe glabellar lines for certain adult patients and marketed by Evolus, Inc. under the name Jeuveau in the U.S. and Nuceiva in Canada and the European Union. We have exclusive development and distribution rights for therapeutic uses of ABP-450 in the U.S., Canada, the European Union, the United Kingdom, and certain other international territories. We have built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization.

We originally intended to pursue a submission of a BLA under Section 351(a) of the Public Health Service Act, or an Original BLA, seeking one or more potential therapeutic indications for ABP-450. We had completed a Phase 2 study of ABP-450 for the treatment of cervical dystonia and completed enrollment and dosing of patients for a Phase 2 double blind study of ABP-450 for the treatment of both chronic and episodic migraine. However, our Phase 2 clinical trials for episodic and chronic migraine did not meet their respective primary endpoints. In May 2024, we announced the discontinuation of our Phase 2 clinical trials for episodic and chronic migraine in order to implement certain cash preservation measures.

On July 9, 2024, we announced a strategic reprioritization to pursue a 351(k) biosimilar regulatory pathway for ABP-450, using AbbVie Inc.’s product Botox as a proposed reference product for all of the indications for which Botox is approved, other than the cosmetic uses for which we do not hold development or commercialization rights.

The FDA regulates biosimilars under the Public Health Service Act’s 351(k) pathway, which requires developers to demonstrate that a proposed product is highly similar to an approved reference biologic with no clinically meaningful differences in safety, purity, or potency. Analytical similarity is the scientific foundation of this process, representing the most critical and data-intensive phase of development. Once analytical comparability across key quality attributes is established, subsequent FDA interactions focus on confirming whether any residual uncertainty requires limited clinical evaluation.

We held an initial meeting with the FDA in the third quarter of 2024 during which we aligned with the FDA on next steps to develop a Botox biosimilar. We commenced analytical studies in the fourth quarter of 2024 to prepare for an anticipated, now confirmed BPD Type 2a meeting with the FDA on November 19, 2025 to review the results from the analytical studies, including comparative primary structure analysis and select functional analyses.

The initial results from our analytical studies indicate a 100% amino acid sequence match confirmed between ABP-450 and Botox, based on sequence coverage of 93% to 99% for the five proteins that comprise the 900kD botulinum toxin type A complex, using liquid chromatography/mass spectrometry (“LC/MS”) analysis of more than 3,400 peptides across multiple lots of ABP-450 and Botox, without any sequence deviations observed. Additionally, ABP-450 also demonstrated highly similar potency across two distinct assays (LD50 - in vivo biological activity and CBPA - cell-based potency assay) to support clinical dose predictability, comparable vial to vial active ingredient composition using ELISA - further supporting dose similarity and reliability, and functional 26

Table of Contents cleavage of SNAP-25, consistent with the mechanism of action. The Company expects to perform additional analyses to seek regulatory approval of ABP-450 as a biosimilar to Botox for therapeutic indications.

Botulinum toxins represent a well-characterized class of biologic therapeutics with over 230 potential therapeutic uses documented in the published scientific literature and twelve FDA-approved indications in the United States. ABP-450 has been previously evaluated in multiple clinical and preclinical programs, including Phase 2 studies in cervical dystonia and migraine and preclinical work in gastroparesis and neuropsychiatric models. The Phase 2 cervical dystonia program met its primary and key secondary endpoints and, together with its open-label safety extension, provides human clinical data supporting the safety and efficacy of ABP-450. We are not currently pursuing additional 351(a) indication-specific development programs, but we retain related intellectual property and know-how that could support future collaborations or lifecycle opportunities.

We license ABP-450 from Daewoong, a South Korean pharmaceutical manufacturer, and have exclusive development and distribution rights for therapeutic indications in the U.S., Canada, the European Union, the United Kingdom, and certain other international territories. Daewoong licenses the same 900 kDa botulinum toxin to Evolus for cosmetic indications, which Evolus markets and sells under the name Jeuveau in the United States and Nuceiva in Canada and the European Union. Prior to licensing the botulinum toxin complex to Evolus, Daewoong conducted a broad preclinical development program for ABP-450 that was primarily focused on safety to support any clinical indication. Subsequently, Evolus completed a comprehensive clinical development program of the same botulinum toxin complex and has received approval from regulatory authorities in the United States, the European Union and Canada to market and sell Jeuveau in the United States and Nuceiva in Canada and the European Union for the temporary improvement in the appearance of moderate to severe glabellar, or frown, lines in adults. Over 2,100 adult subjects with moderate to severe glabellar lines at maximum frown participated in Evolus’ clinical development program, and each of Evolus’ Phase 3 clinical studies successfully met their respective primary safety and efficacy endpoints. While none of these preclinical or clinical programs specifically contemplated any therapeutic use of ABP-450, given that the FDA’s regulatory requirements are generally the same for the cosmetic or therapeutic use of a toxin, we believe that the positive data derived from these preclinical and clinical studies will support the clinical development and anticipated future safety labeling of ABP-450 for our 351(k) biosimilar program, across all labeled dose ranges.

We plan to pursue approval of a BLA under Section 351(k) that exclusively contemplates therapeutic indications for ABP-450, which we believe could improve provider reimbursement for ABP-450, if approved. Existing botulinum toxins, including Botox, are approved under a single BLA for both therapeutic and cosmetic indications. As a result, other botulinum toxins are required to include the sales prices of both therapeutic and cosmetic botulinum toxin sales when calculating the average selling price, or ASP, that is used to determine the reimbursement amount physicians receive for therapeutic usage. The inclusion of a lower cosmetic sales price in the calculation of ASP can cause physicians that inject for therapeutic applications to lose money when treating patients with existing botulinum toxins and also creates a deterrent to providing payors and/or providers with rebates or other financial incentives. If we are successful in obtaining a BLA under Section 351(k) for therapeutic indications of ABP-450, the ASP for ABP-450 would be calculated using only therapeutic sales, which we believe would facilitate consistent and favorable product reimbursement to physicians when they choose to use ABP-450 for therapeutic treatments, as well as the ability to provide payors and/or providers with rebates and other financial incentives. This pricing model would be unique to us within the current therapeutic neurotoxin market, and we believe it would allow physicians to provide treatment with ABP-450 at a more competitive or the same net price as the market leader after rebates and discounts.

We have never been profitable from operations and, as of September 30, 2025, we had an accumulated deficit of $433.7 million. We have never generated revenue from ABP-450. We have concluded that we do not have sufficient cash to fund our operations for 12 months from the date of our financial statements without additional financing, and as a result, there is substantial doubt about our ability to continue as a going concern. As of the date of this Report, we expect to have sufficient cash to fund our operating plan into the second quarter of 2026, including funds anticipated to be received from the first and second closings of the PIPE Financing in November 2025. Any further development of ABP-450 for any indication, including the biosimilar pathway and any additional studies, will require additional funding, which may not be available to us on reasonable terms, or at all.

We do not expect to receive any revenue from ABP-450 or any future product candidates that we develop unless and until we obtain regulatory approval and commercialize ABP-450 or any future product candidates. We expect to continue to incur significant expenses and increasing net operating losses for the foreseeable future as we seek regulatory approval, prepare for and, if approved, proceed to commercialization of ABP-450. 27

Table of Contents

Executive Overview

On April 19, 2025, the board of directors (the “Board”) appointed Robert Bancroft as the Company’s Principal Executive Officer, President, Chief Executive Officer and member of the Board, effective as of April 29, 2025, in connection with Marc Forth’s resignation as the Company’s President and Chief Executive Officer. Mr. Bancroft reports directly to the Board. Mr. Forth continues to serve as a member of the Board.

Liquidity and Capital Resources and Going Concern

As disclosed further below in the section titled “Liquidity and Capital Resources”, we have incurred operating losses and negative cash flows from operating activities since inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2025, we had reported cash and cash equivalents of $5.9 million and an accumulated deficit of $433.7 million. As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists as conditions and events, considered in the aggregate, indicate that it is probable that we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this Report are issued. Our ability to continue as a going concern is dependent upon our ability to successfully accomplish our business plans and secure sources of financing and ultimately attain profitable operations.

Notice of Noncompliance

​

On February 3, 2025, the Company received a written notice of non-compliance (the “Notice”) from NYSE American stating that the Company is not in compliance with continued listing standards of Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”), which requires stockholders’ equity of $2.0 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years (the “Minimum Requirement”), as defined in Section 1003(a)(i) of the Company Guide. Pursuant to the Notice, the Company reported a stockholders’ deficit of $32.1 million at September 30, 2024 and has had losses in the two most recent fiscal years ended December 31, 2023 based on the Company’s Annual Report on Form 10-K/A filed with the U.S. Securities and Exchange Commission on May 14, 2024, and the Company is not currently eligible for any exemption from the stockholders’ equity requirement in Section 1003(a) of the Company Guide, and as such, NYSE American deems the Company below compliance with the Minimum Requirement. As required by the Notice, the Company submitted a plan to regain compliance with the continued listings standards of the Company Guide (the “Plan”).

On April 22, 2025, the Company received a notification (the “Acceptance Letter”) from NYSE American that the Plan was accepted. In the Acceptance Letter, NYSE American granted the Company until August 3, 2026 (the “Plan Period”) to regain compliance with the continued listing standards. During the Plan Period, the Company will be subject to periodic review by NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide during the Plan Period. If the Company does not regain compliance with NYSE American listing standards by August 3, 2026, or if the Company does not make sufficient progress consistent with the Plan during the Plan Period, then NYSE American may initiate delisting proceedings.

The Acceptance Letter has no immediate impact on the listing of the Company’s shares of Class A common stock, par value $0.0001 per share (the “Common Stock”), which will continue to be listed and traded on NYSE American during the Plan Period, subject to the Company’s compliance with the other listing requirements of NYSE American. The Common Stock will continue to trade under the symbol “AEON”. The Acceptance Letter does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission. The Company intends to consider available options to resolve the non-compliance with the Minimum Requirement by August 3, 2026. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Requirement. 28

Table of Contents Convertible Note Subscription

On March 19, 2024, we entered into the Subscription Agreement with Daewoong relating to our sale and issuance of the Convertible Notes in the principal amount of up to $15.0 million, which are convertible into shares of Common Stock, subject to certain conditions and limitations set forth in each Convertible Note. Each Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date that is three years from the funding date (the “Maturity Date”), unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. We will use the net proceeds from each Convertible Note to support the late-stage clinical development of ABP-450 and for general working capital purposes. Pursuant to the terms of the Subscription Agreement, on March 24, 2024, we issued and sold to Daewoong one Convertible Note in the principal amount of $5.0 million and, on April 12, 2024, we issued and sold to Daewoong an additional Convertible Note in the principal amount of $10.0 million.

On March 19, 2024, we entered into a Fourth Amendment to the License Agreement (the “License Agreement Amendment”) with Daewoong, which amends that certain License and Supply Agreement, by and between us and Daewoong, dated December 20, 2019, as amended on July 29, 2022, January 8, 2023 and April 24, 2023 (the “License Agreement”). Pursuant to the terms of the License Agreement Amendment, the License Agreement will terminate if, over any six-month period, (a) we cease to commercialize ABP-450 in certain territories specified in the License Agreement and (b) we cease to advance any clinical studies of ABP-450 in such territories. The License Agreement Amendment also provides that, in the event that the License Agreement is terminated for the foregoing reasons, Daewoong will have the right to purchase all Know-How (as defined in the License Agreement) related to ABP-450 for a price of $1.00 (the “Termination Purchase Right”). The Termination Purchase Right will terminate and expire upon Daewoong’s sale of 50% of its common stock, including common stock held by its affiliates and common stock that would be issued upon an Automatic Conversion or Optional Conversion (as defined below).

If, prior to the Maturity Date, the Company consummates a bona-fide third-party financing in the form of Common Stock or any securities convertible into, or exchangeable or exercisable for, Common Stock (subject to certain exceptions as described in each Convertible Note), in one or more transactions or a series of related and substantially similar and simultaneous transactions at the same purchase price from third parties unaffiliated with Daewoong and its affiliates, for aggregate gross cash proceeds to the Company of at least $30.0 million (a “Qualified Financing”), then, upon written notice thereof to Daewoong by the Company, on the closing date of such Qualified Financing, each Convertible Note will automatically convert in whole (the “Automatic Conversion”) (subject to any limitations under the rules and regulations of NYSE American), without any further action by Daewoong, into a number of shares equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of each Convertible Note and all accrued and unpaid interest to be converted divided by (b) the per share price of the common stock sold in the Qualified Financing, provided that such per share price of common stock is at least $1.00 per share.

If, prior to the Maturity Date, the Company provides (i) written notice to Daewoong that it has publicly announced topline clinical data regarding its Phase 3 clinical study of ABP-450 for the treatment of chronic or episodic migraine, and such data indicates achievement of all primary endpoints or (ii) a written notice that the Company has consummated a Change of Control (as defined in each Convertible Note), Daewoong will have the right for thirty (30) days following receipt of either such notice, at Daewoong’s option (the “Optional Conversion”), to convert all (but not less than all) of the remaining outstanding portion of each Convertible Note (subject to any limitations under the rules of NYSE American) into an amount of shares of common stock equal to: (i) one and three tenths (1.3) multiplied by (ii) the quotient of (a) the principal amount of each Convertible Note and all accrued and unpaid interest to be converted divided by (b) the volume weighted average trading per share price of common stock over the five (5) trading days prior to the Company’s receipt of Daewoong’s written notice of exercise of the Optional Conversion, provided that such per share price of common stock is at least $1.00 per share.

On November 13, 2025, the Company announced that it has entered into a binding term sheet with Daewoong contemplating the exchange of the 2024 Convertible Notes of $15.0 million in principal plus accrued interest for approximately 23,103,694 shares of Class A common stock (or pre-funded warrants in lieu of shares), a $1.5 million new convertible note due 2030 with interest rate of 15.79%, and approximately 8 million cash-exercise warrants on the same term as the PIPE Warrants (the “Exchange”). The parties expect to enter into definitive documentation for the Exchange in the coming weeks following execution of definitive documentation. The consummation of the Exchange will be subject to stockholder approval. 29

Table of Contents Public Offering

On January 6, 2025, we entered into an underwriting agreement with Aegis Capital Corp. (“Aegis” or the “Underwriter”) pursuant to which the Company agreed to sell and issue, in an underwritten public offering (the “Offering”) 555,571 Common Units, each consisting of (i) one (1) share of Common Stock, (ii) one (1) Series A Registered Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $45.00 (the “Series A Warrants”) and (iii) one (1) Series B Registered Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $45.00 (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”). Additionally, the Company granted Aegis a 45-day option to purchase additional shares of Common Stock and/or Warrants of (i) up to 15.0% of the number of shares of Common Stock sold in the offering, (ii) up to 15.0% of the number of Series A Warrants sold in the offering and (iii) up to 15.0% of the number of Series B Warrants sold in the offering. The purchase price per additional share of Common Stock is equal to the public offering price of one Common Unit (less $0.01 allocated to each full Warrant), less the underwriting discount. The purchase price per additional Warrant is $0.01. On January 7, 2025, Aegis exercised its over-allotment option with respect to 83,334 Series A Warrants and 83,334 Series B Warrants.

The closing of the Offering occurred on January 7, 2025. The Company received net proceeds of approximately $18.3 million from the Offering, after deducting the offering expenses payable by the Company, including the Underwriter’s fees and expenses. The Company intends to use the net proceeds from the Offering for general corporate purposes, including working capital.

PIPE Financing

On November 12, 2025, the Company entered into a securities purchase agreement for a private placement (“PIPE”) financing for: (i) the sale of 6,581,829 shares of the Company’s Class A common stock (or pre-funded warrants in lieu of shares) at a price per share of $0.9116, for gross proceeds of $6 million; (ii) five-year warrants to purchase up to 6,581,829 shares of Class A common stock at an exercise price of $1.094 per share (the “PIPE Warrants”); and (iii) the investors’ rights to receive anti-dilutive warrants following the exchange of the Daewoong 2024 Convertible Notes, for a number of shares not to exceed 6,581,829 shares (the “anti-dilutive Warrants”). The PIPE financing will close in two stages. The first closing is expected to occur in November 2025, subject to the satisfaction of customary closing conditions, and result in $1.79 million in gross proceeds to the Company. The second closing will be subject to stockholder approval, the closing of the exchange of the Daewoong 2024 Convertible Notes, and other customary closing conditions. The PIPE Warrants and anti-dilutive Warrants will be issued only at the second closing. The Company plans to use net proceeds to further advance analytical work for its ABP-450 biosimilar program, and for general corporate purposes.

Components of Our Results of Operations

Revenue

We have generated no revenue from the sale of products and do not anticipate deriving any product revenue unless and until we receive regulatory approval for, and are able to successfully commercialize, ABP-450.

Operating Expenses

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses, consist primarily of compensation for personnel, including stock-based compensation, management, finance, legal, and regulatory functions. Other SG&A expenses include travel expenses, market research and analysis, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs, general corporate expenses, and allocated facilities-related expenses. As we pivot to our biosimilar strategy, we anticipate that our SG&A expenses will decrease in the near-future to focus our resources to research and development (“R&D”) activities. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of NYSE American and the SEC, insurance, and investor relations costs. We expect to incur increased costs associated with establishing sales, marketing, and commercialization functions in advance of potential future regulatory approvals and commercialization of our product candidates. If ABP-450 obtains United States regulatory approval for any 30

Table of Contents indication, we expect that we would incur significantly increased expenses associated with building a sales and marketing team and funding commercial activities.

Research and Development Expenses

Our R&D expenses are primarily attributed to the development of ABP-450 as a biosimilar product in the United States through a Section 351(k) BLA, using AbbVie Inc.’s product Botox as a proposed reference product for all of the indications for which Botox is approved, other than the cosmetic uses for which we do not hold development or commercialization rights, which may include initiating a comparability study of ABP-450 in one or more of the indications currently approved for use by the proposed reference product. Due to the stage of our development and our ability to use resources across all of our programs, most of our R&D costs are not recorded on a program-specific basis. We expect our R&D expenses to increase as we, subject to raising additional capital, develop and seek regulatory approval of ABP-450. R&D expenses associated with these activities may include third-party costs such as expenses incurred under agreements with clinical research organizations, the cost of consultants who assist with the development of ABP-450 on a program-specific basis, investigator grants, sponsored research, product costs in connection with acquiring ABP-450 from Daewoong and Botox for use in conducting preclinical and clinical studies, and other third-party expenses attributable to the development of our product candidates.

R&D activities will be critical to achieving our business strategy. The biosimilar pathway will require significant costs in order to design, execute and complete the primary structural analysis and any additional analyses. Any clinical studies, such as a comparability study in any of the indications currently approved for use by the proposed reference product, will generally incur greater development costs than those programs incurred in the earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical studies. We expect our R&D expenses to be significant over the next years as we pursue the development of ABP-450 as a biosimilar and seek regulatory approval using Botox as the reference product. As a result, we are unable to determine the duration and completion costs of our programs or when and to what extent we will generate revenue from commercialization and sale of any of our product candidates. Our R&D activities may be subject to change from time to time as we evaluate our strategic plan, priorities and available resources.

Change in Fair Value of Contingent Consideration

The Company determined that the Contingent Consideration would be classified as a liability on the consolidated balance sheets and remeasured at each reporting period with changes to fair value recorded to the consolidated statements of operations and comprehensive (loss) income.

Other (Loss) Income, Net

Other (loss) income, net primarily consists of gains and losses resulting from the remeasurement of the fair value of our convertible notes, warrant liabilities, forward purchase agreements, and loss on issuance of warrants, each described below, at each balance sheet date.

Change in fair value of convertible notes – The Company elected the fair value option to account for its convertible notes, with the subsequent changes in fair value recorded in the consolidated statement of operations and comprehensive (loss) income.

Change in fair value of warrants - Changes in the estimated fair value of our warrant liabilities are recognized as a non-cash gain or loss on the consolidated statements of operations and comprehensive (loss) income.

Loss on embedded forward purchase agreement and make whole derivative - the Company has determined that each of its forward purchase agreements entered in connection with the Merger is a freestanding hybrid financial instrument comprising a subscription receivable and embedded features, which were bifurcated and accounted for separately as derivative instruments. The Company recorded the derivatives as liabilities and measured them at fair value. Subsequent changes in the bifurcated derivatives are recorded in the consolidated statements of operations and comprehensive (loss) income. Upon termination of the forward purchase agreements in the first quarter of fiscal 2024, the Company recorded a charge to the consolidated statement of operations of $20.3 million to reverse the related subscription receivable and derivative liability on the accompanying consolidated balance sheet.

Loss on issuance of warrants – the Company’s issued Warrants in the first quarter of 2025 had grant date fair values of $94.0 million on January 7, 2025 and was recorded as a liability as of grant date. Proceeds were allocated to the warrant liability based on 31

Table of Contents the fair value as of grant date of the warrants of $94.0 million. As the fair value of the warrants issued were greater than the proceeds received, the Company recognized a loss on issuance of warrants of $75.6 million.

Results of Operations

The following table summarizes our results of operations for the periods indicated (in thousands):

​	​	​	​	​	​	​	​	​	​	​	​	​	​
​	****	Three Months Ended					​	Nine Months Ended					​
​	​	September 30,					​	September 30,					​
​	​	2025			2024		​	2025			2024		​
Operating expenses:		​	​		​	​	​	​	​	​	​		​
Selling, general and administrative	​	$	1,933	​	$	3,044	​	$	8,316	​	$	11,014	​
Research and development	​		597	​		972	​		2,485	​		11,144
Change in fair value of contingent consideration	​		(37)	​		—	​		(3,509)	​		(97,464)
Total operating costs and expenses	​		2,493	​		4,016	​		7,292	​		(75,306)
(Loss) income from operations	​		(2,493)	​		(4,016)	​		(7,292)	​		75,306
Other (loss) income:	​			​			​			​
Change in fair value of convertible notes	​		(1,877)	​		(1,878)	​		(5,362)	​		(170)
Change in fair value of warrants	​		(236)	​		(377)	​		85,950	​		(15,376)
Loss on issuance of warrants	​	​	—	​	​	—	​	​	(75,644)	​		—
Loss on embedded forward purchase agreements and derivative liabilities, net	​	​	—	​	​	81	​	​	—	​		(19,931)
Other income, net	​		68	​		19	​		263	​		94
Total other (loss) income, net	​		(2,045)	​		(2,155)	​		5,207	​		(35,383)
(Loss) income before taxes	​		(4,538)	​		(6,171)	​		(2,085)	​		39,923
Income taxes	​		—	​		—	​		—	​		—
Net (loss) income	​	$	(4,538)	​	$	(6,171)	​	$	(2,085)	​	$	39,923	​
Basic net (loss) income per share	​	$	(0.39)	​	$	(11.24)	​	$	(0.23)	​	$	74.53	​
Diluted net (loss) income per share	​	$	(0.39)	​	$	(11.24)	​	$	(0.23)	​	$	69.53	​
Weighted average shares of common stock outstanding used to compute basic net (loss) income per share	​	​	11,634,946	​	​	549,175	​	​	8,931,566	​	​	535,693	​
Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share	​		11,634,946	​		549,175	​		8,931,566	​		574,216

Comparison of the three and nine months ended September 30, 2025 and 2024

Operating Expenses

Selling, General and Administrative (SG&A) Expenses

SG&A expenses were $1.9 million for the three months ended September 30, 2025, resulting in a decrease of $1.1 million, or 36%, compared to $3.0 million during the three months ended September 30, 2024. The decrease in SG&A expenses was primarily attributable to a decrease of $1.0 million related to reversal of share-based compensation expense related to restricted stock units (“RSU”) with earnout criteria determined to be improbable in the third quarter of 2025, $0.4 million gain on the settlement with Odeon in the third quarter of 2025 and a $0.1 million decrease in business insurance costs due to lower renewal premiums, offset by $0.5 million of expense related to cash-settled restricted stock units (“RSU”) that were issued in the second quarter of 2025.

SG&A expenses were $8.3 million for the nine months ended September 30, 2025, resulting in a decrease of $2.7 million, or 25%, compared to $11.0 million during the nine months ended September 30, 2024. The decrease in SG&A expenses was primarily attributable to a decrease of $1.0 million related to reversal of share-based compensation expense related to RSU with earnout criteria determined to be improbable in the third quarter of 2025, $1.2 million decrease in legal expenses and professional fees for the Company’s registration statement filings in the prior year, $0.4 million gain on the settlement with Odeon in the third quarter of 2025, $0.4 million decrease in business insurance costs due to lower renewal premiums and a $0.3 million decrease in salaries due to headcount reduction in the prior year to preserve cash, offset by $0.7 million of expense related to cash-settled RSU that were issued in the second quarter of 2025. 32

Table of Contents Research and Development (R&D) Expenses

R&D expenses were $0.6 million for the three months ended September 30, 2025, a decrease of $0.4 million, or 40%, compared to $1.0 million for the three months ended September 30, 2024. The decrease was primarily attributable to $1.1 million decrease in R&D expenses due to wind down of Phase 2 clinical trials related to chronic and episodic migraine and cervical dystonia, including $0.6 million gain related to settlement of outstanding liabilities with the Company’s clinical research organization related to its cervical dystonia and migraine programs, offset by an increase of $0.7 million for biosimilar consulting.

R&D expenses were $2.5 million for the nine months ended September 30, 2025, a decrease of $8.7 million, or 80%, compared to $11.1 million for the nine months ended September 30, 2024. The decrease was primarily attributable to a $9.4 million decrease in R&D expenses due to wind down of Phase 2 clinical trials related to chronic and episodic migraine and cervical dystonia, including $0.6 million related to settlement of outstanding liabilities with the Company’s clinical research organization related to its cervical dystonia and migraine programs, and $0.3 million decrease in salaries due to headcount reduction in the prior year to preserve cash, offset by an increase of $1.1 million for biosimilar consulting.

Change in Fair Value of Contingent Consideration

The Company recognized gains of de minimus and $3.5 million for the three and nine months ended September 30, 2025, respectively, related to the change in the fair value of the contingent consideration related to certain contingent provisions, restrictions and forfeiture provisions for Founder Shares and certain Participating Stockholders shares. The gain was primarily due to a decrease in the Company’s stock price from $38.88 to $0.81 as of December 31, 2024 and September 30, 2025, respectively. For the three and nine months ended September 30, 2024, the Company recognized gains of $0 and $97.5 million, respectively, primarily due to changes in the milestone probabilities in the second quarter of 2024 following the announcement of the Company’s topline Phase 2 migraine results and fluctuations in the Company’s stock price from $518.40 to $75.60 as of December 31, 2023 and September 30, 2024, respectively.

Loss on Issuance of Warrants

The Company’s issued Warrants in the first quarter of 2025 had grant date fair values of $94.0 million on January 7, 2025 and was recorded as a liability as of grant date. Proceeds were allocated to the warrant liability based on the fair value as of grant date of the warrants of $94.0 million. As the fair value of the warrants issued were greater than the proceeds received, the Company recognized a loss on issuance of warrants of $75.6 million.

Other Income, Net

For the three and nine months ended September 30, 2025 and September 30, 2024, the Company recognized losses of $1.9 million, $5.4 million, $1.9 million, and $0.2 million related to change in fair value of convertible notes due to changes in stock price and conversion probabilities of the Daewoong convertible notes.

For the three months ended September 30, 2025 and 2024, the Company recognized losses of $0.2 million and $0.4 million, respectively, related to the change in fair value of warrants.

For the nine months ended September 30, 2025 and September 30, 2024, the Company recognized income of $86.0 million, offset by $75.6 million from fair value loss at issuance related to Series A and Series B warrants issued in the first quarter of fiscal 2025, compared to a loss of $15.4 million in the prior year, related to warrants issued at the Closing.

For the nine months ended September 30, 2024, the Company recognized a loss of $19.9 million related to the termination of the forward purchase agreements in 2024.

Liquidity and Capital Resources

Our primary sources of capital have been debt and equity financing. We have experienced recurring losses from operations and have a net capital deficiency and negative cash flows from operations since our inception. As of September 30, 2025, we had reported cash and cash equivalents of $5.9 million and an accumulated deficit of $433.7 million. 33

Table of Contents On March 19, 2024, we entered into the Subscription Agreement with Daewoong relating to our sale and issuance of Convertible Notes in the principal amount of up to $15.0 million, which are convertible into shares of common stock, subject to certain conditions and limitations set forth in each Convertible Note. Each Convertible Note will contain customary events of default, will accrue interest at an annual rate of 15.79% and will have a maturity date that is three years from the funding date, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. We will use the net proceeds from each Convertible Note to support the late-stage clinical development of ABP-450 and for general working capital purposes. Pursuant to the terms of the Subscription Agreement, on March 24, 2024, the Company issued and sold to Daewoong one Convertible Note in the principal amount of $5.0 million, and on April 12, 2024, the Company issued and sold to Daewoong one Convertible Note in the principal amount of $10.0 million.

​

On March 19, 2024, we entered into the License Agreement Amendment with Daewoong, which amends the License Agreement. Pursuant to the terms of the License Agreement Amendment, the License Agreement will terminate if, over any six-month period, (a) we cease to commercialize ABP-450 in certain territories specified in the License Agreement and (b) we cease to advance any clinical studies of ABP-450 in such territories. The License Agreement Amendment also provides that, in the event that the License Agreement is terminated for the foregoing reasons, Daewoong will have the right to purchase all Know- How (as defined in the License Agreement) related to ABP-450 for a price of $1.00. The Termination Purchase Right will terminate and expire upon Daewoong’s sale of 50% of its common stock, including common stock held by its affiliates and common stock that would be issued upon an Automatic Conversion or Optional Conversion (as defined in the Convertible Notes).

​

On November 13, 2025, the Company announced that it has entered into a binding term sheet with Daewoong contemplating the exchange of the 2024 Convertible Notes of $15.0 million in principal plus accrued interest for approximately 23,103,694 shares of Class A common stock (or pre-funded warrants in lieu of shares), a $1.5 million new convertible note due 2030 with interest rate of 15.79%, and approximately 8 million cash-exercise warrants on the same term as the PIPE Warrants (the “Exchange”). The parties expect to enter into definitive documentation for the Exchange in the coming weeks following execution of definitive documentation. The consummation of the Exchange will be subject to stockholder approval.

​

On May 3, 2024, we announced preliminary top-line results from a planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine, which did not meet the primary or secondary endpoints. We originally intended to pursue submission of an Original BLA seeking one or more potential therapeutic indications for ABP-450. However, in May 2024, we announced the discontinuation of our Phase 2 clinical trials for episodic and chronic migraine in order to implement certain cash preservation measures.

​

On July 9, 2024, we announced a strategic reprioritization to pursue a 351(k) biosimilar regulatory pathway for ABP-450, using AbbVie Inc.’s product Botox as a proposed reference product for all of the indications for which Botox is approved, other than the cosmetic uses.

​

We held an initial meeting with the FDA in the third quarter of 2024 during which we aligned with the FDA on next steps to develop a Botox biosimilar. We commenced analytical studies in the fourth quarter of 2024 to prepare for an anticipated, now confirmed BPD Type 2a meeting with the FDA on November 19, 2025 to review the results from the studies. However, the commencement of studies, preparation for an expected BPD meeting and any further development of ABP-450 would require additional funding in the form of equity financings or debt. There can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be commercially acceptable. Furthermore, the use of equity as a source of financing would dilute existing shareholders.

​

On January 6, 2025, we entered into an underwriting agreement with Aegis pursuant to which we agreed to sell and issue, in an underwritten public offering (the “Offering”) 555,571 Common Units, each consisting of (i) one (1) share of Common Stock, (ii) one (1) Series A Registered Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $45.00 (the “Series A Warrants”) and (iii) one (1) Series B Registered Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $45.00 (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”). Additionally, the Company granted Aegis a 45-day option to purchase additional shares of Common Stock and/or Warrants of (i) up to 15.0% of the number of shares of Common Stock sold in the offering, (ii) up to 15.0% of the number of Series A Warrants sold in the offering and (iii) up to 15.0% of the number of Series B Warrants sold in the offering. The purchase price per additional share of Common Stock is equal to the public offering price of one Common Unit (less $0.01 allocated to each full Warrant), less the underwriting discount. The purchase price per additional Warrant is $0.01. On January 7, 2025, Aegis exercised its over-allotment option with respect to 83,334 Series A Warrants and 83,334 Series B Warrants. The Offering closed on January 7, 2025, and the Company received net proceeds of 34

Table of Contents approximately $18.3 million from the Offering, after deducting the offering expenses payable by the Company, including the Underwriter’s fees and expenses.

​

On November 12, 2025, the Company entered into a securities purchase agreement for a private placement (“PIPE”) financing for: (i) the sale of 6,581,829 shares of the Company’s Class A common stock (or pre-funded warrants in lieu of shares) at a price per share of $0.9116, for gross proceeds of $6 million; (ii) five-year warrants to purchase up to 6,581,829 shares of Class A common stock at an exercise price of $1.094 per share (the “PIPE Warrants”); and (iii) the investors’ rights to receive anti-dilutive warrants following the exchange of the Daewoong 2024 Convertible Notes, for a number of shares not to exceed 6,581,829 shares (the “anti-dilutive Warrants”). The PIPE financing will close in two stages. The first closing is expected to occur in November 2025, subject to the satisfaction of customary closing conditions, and result in $1.79 million in gross proceeds to the Company. The second closing will be subject to stockholder approval, the closing of the exchange of the Daewoong 2024 Convertible Notes, and other customary closing conditions. The PIPE Warrants and anti-dilutive Warrants will be issued only at the second closing. The Company plans to use net proceeds to further advance analytical work for its ABP-450 biosimilar program, and for general corporate purposes.

​

As of the date of this Report, we expect to have sufficient cash to fund our operating plan into the second quarter of 2026, including funds anticipated to be received from the first and second closings of the PIPE Financing in November 2025. We will actively attempt to secure additional capital to fund our operations. However, we cannot assure you that we will be able to raise additional capital on commercially reasonable terms or at all.

​

We have incurred operating losses and negative cash flows from operating activities since inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. Our primary use of cash is to fund operating expenses, which consist of R&D expenditures, including clinical trials, as well as SG&A expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay or prepay these expenses. We expect to continue to incur substantial costs in order to conduct R&D activities necessary to develop and commercialize our product candidates. Until such time, if ever, as we can generate substantial product revenue from sales of ABP-450, we will need additional capital to undertake these activities and commercialization efforts, and, therefore, we intend to raise such capital through the issuance of additional equity, borrowings, and potentially strategic alliances with other companies. However, if such financing is not available at adequate levels or on acceptable terms, we could be required to reduce the scope of or eliminate some of our development programs or commercialization efforts, out-license intellectual property rights to our product candidates or sell unsecured assets, or a combination of the above, any of which may have a material adverse effect on our business, results of operations, financial condition and/or our ability to fund our scheduled obligations on a timely basis or at all. Our ability to continue as a going concern is dependent upon our ability to successfully accomplish these plans and secure sources of financing and ultimately attain profitable operations.

​

We may also seek to raise additional capital through the sale of public or private equity or convertible debt securities. If we incur additional debt, the debt holders would have rights senior to holders of common stock to make claims on our assets, and the terms of any debt could restrict our operations, including our ability to pay dividends to holders of our common stock. If we undertake discretionary financing by issuing equity securities or convertible debt securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at a price per share that is less than the price per share paid by current public stockholders. If we sell common stock, convertible securities, or other equity securities in more than one transaction, stockholders may be further diluted by subsequent sales. Additionally, future equity financings may result in new investors receiving rights superior to our existing stockholders. Because our decision to issue securities in the future will depend on numerous considerations, including factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future issuances of debt or equity securities. As a result, our stockholders bear the risk of future issuances of debt or equity securities reducing the value of our common stock and diluting their interests.

​

We may receive additional capital from the cash exercise of the Private Placement Warrants. However, the exercise price of our Private Placement Warrants is $828.00 per warrant and the last reported sales price of our common stock on November 10, 2025 was $0.935. The likelihood that holders of the Private Placement Warrants will exercise their Private Placement Warrants, and therefore the likelihood of any amount of cash proceeds that we may receive, is dependent upon the trading price of our common stock after effectiveness of the registration statement related thereto registering the issuance of common stock underlying the Private Placement Warrants. If the trading price for our common stock does not maintain a price above $828.00 per share, we do not expect holders to exercise their Warrants for cash. We will have broad discretion over the use of any proceeds from the exercise of such securities. Any proceeds from the exercise of such securities would increase our liquidity, but we are not currently budgeting for any cash proceeds from the exercise of the Private Placement Warrants when planning for our operational funding needs. The Private Placement 35

Table of Contents Warrants may be exercised on a cashless basis at any time and we will not receive any proceeds from such exercise, even if the Private Placement Warrants are in-the-money.

​

To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product licenses on terms that may not be favorable to us. If these sources are insufficient to satisfy our liquidity requirements, we will seek to raise additional funds through future equity or debt financings. If we raise additional funds by issuing equity securities, our stockholders would experience dilution. Additional debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. There can be no assurance that our efforts to procure additional financing will be successful or that, if they are successful, the terms and conditions of such financing will be favorable to us or our stockholders. If we are unable to raise additional financing when needed, we may be required to delay, reduce, or terminate the development, commercialization and marketing of our products and scale back our business and operations.

​

As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists as conditions and events, considered in the aggregate, indicate that it is probable that we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this Report are issued. Our financial information throughout this Report and our financial statements included elsewhere in this Report have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. This financial information and our consolidated financial statements do not include any adjustments that may result from an unfavorable outcome of this uncertainty. Our ability to continue as a going concern is dependent upon our ability to successfully accomplish our business plans and secure sources of financing and ultimately attain profitable operations.

Net Cash Used in Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2025 was $12.6 million, consisting of a net loss of $2.1 million, non-cash gain of $4.7 million and changes in operating assets and liabilities of $5.8 million. Non-cash gain primarily consists of $86.0 million decrease related to change in fair value of warrants and $3.5 million decrease related to change in fair value of contingent consideration, offset by $75.6 million loss on issuance of warrants, $3.7 million related to stock-based compensation for our executives and directors and $5.4 million related to the change in fair value of the convertible notes. Decrease in cash used in operating activities of $7.1 million is primarily attributable to timing of clinical trial payments.

Net cash used in operating activities for the nine months ended September 30, 2024 was $19.7 million, consisting primarily of a net income of $39.9 million and non-cash charges of $(57.0) million, consisting primarily of $4.9 million non-cash expense related to stock-based compensation for our executives and directors, $0.2 million related to the change in fair value of the convertible notes, $15.4 million related to change in fair value of warrants, $19.9 million related to loss on forward purchase agreement and derivative liabilities, and $(97.5) million related to change in fair value of contingent consideration.

Cash Flows from Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2025 and 2024 were a de minimus amount and zero, respectively, related to the purchase of property and equipment.

Cash Flows from Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2025 and 2024 were $18.5 million and $15.1 million, respectively, primarily related to the public offering in the first quarter of fiscal 2025 and proceeds from issuance of convertible notes in the first and second quarters of fiscal 2024, respectively.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the financial statements as well as the 36

Table of Contents expenses incurred during the reporting period. Generally, we base our estimates on historical experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions and such differences could be material to the financial position and results of operations. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. As of September 30, 2025, there have been no changes to our critical accounting policies from those reported on our Annual Report Form 10-K.

JOBS Act; Smaller Reporting Company

We are an emerging growth company, as defined in the Securities Act, as modified by the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and any golden parachute payments not previously approved. In particular, in this Report, we have provided only two years of unaudited financial statements and have not included all of the executive compensation- related information that would be required if we were not an emerging growth company. Section 102(b)(2) of the JOBS Act allows us to delay adoption of the new or revised accounting standards until those standards apply to non-public business entities. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.

We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of Priveterra’s initial public offering (December 31, 2026), (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

We are also a “smaller reporting company,” as such term is defined in Rule 12b-2 of the Exchange Act, meaning that the market value of our common stock held by non-affiliates is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We will continue to be a smaller reporting company if either (i) the market value of our common stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.

Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. Investors could find our common stock less attractive to the extent we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the trading price may be more volatile.

Recently Issued and Adopted Accounting Pronouncements

We describe the recently issued accounting pronouncements that apply to us in Note 2 Summary of Significant Accounting Policies of the condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information under this Item.

​

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures 37

Table of Contents Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specific in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Per Rules 13a-15(e) and 15d-15(e), the term disclosure controls and procedures means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, including our chief executive officer and chief financial officer, or persons performing similar functions, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud due to inherent limitations of internal controls. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Our Chief Executive Officer and Chief Accounting Officer (“certifying officers”), in their role as Principal Executive and Financial Officer, have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of September 30, 2025. Our certifying officers concluded that, as a result of the material weaknesses in internal control over financial reporting as described below, our disclosure controls and procedures were not effective as of September 30, 2025.

Our certifying officers concluded that the Company did not have an effective risk assessment over complex transactions due to the lack of sufficient and qualified resources. This also led to a deficiency in the design and implementation of controls over in-process research and development and valuation of financial instruments. We also identified a material weakness related to the lack of segregation of duties in the financial reporting process due to the lack of sufficient resources. Furthermore, the control deficiencies described above created a reasonable possibility that a material misstatement to the consolidated financial statements would not be prevented or detected on a timely basis.

Additionally, as previously disclosed, on July 21, 2023, AEON completed a Merger with Old AEON and Merger Sub, pursuant to which Merger Sub merged with and into Old AEON, with Old AEON surviving the merger as a wholly-owned subsidiary of AEON. Prior to the Merger, Priveterra was a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more target businesses. As a result, previously existing internal controls are no longer applicable or comprehensive enough as of the assessment date considering the Company’s operations prior to the Merger were insignificant compared to those of the Post-Combination Company. The design and implementation of internal controls over financial reporting for the Post-Combination Company has required and will continue to require significant time and resources from management and other personnel.

Remediation Status of Material Weaknesses in Internal Control over Financial Reporting

​

We plan to enhance our processes by designing and implementing controls to review the results of valuations and estimates, including the completeness and accuracy of relevant data elements included in the valuation or estimate. We engaged additional resources during the first quarter of 2025 and are working to ensure incremental controls are properly implemented and to ensure proper segregation of duties around the review of manual journal entries.

Management continues to be actively engaged to take steps to remediate the material weaknesses, including enhanced processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our consolidated financial statements, providing enhanced access to accounting literature, research 38

Table of Contents materials and documents, and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications.

Changes in Internal Control over Financial Reporting

​

Management has continued to take action to remediate the material weaknesses during the nine months ended September 30, 2025. However, the material weaknesses will not be considered remediated until management designs and implements effective controls that operate for a sufficient period of time and management has concluded, through testing, that these controls are effective.

Other than described above, there has not been any changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) during the quarter to which this Report relates that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

​

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

On September 18, 2023, Odeon Capital Group LLC (“Odeon”) filed a lawsuit against the Company in the Supreme Court of the State of New York, alleging that the Company failed to pay Odeon’s deferred underwriting fee of $1.25 million, and seeking monetary damages for the full amount of its claimed underwriting fee, punitive damages, attorneys’ fees and other amounts, totaling approximately $1.7 million, which was recorded in other accrued expenses on the condensed consolidated balance sheets as of December 31, 2024. On October 31, 2025, the Company entered into a settlement agreement with Odeon to settle the lawsuit in exchange for $1.0 million in cash, $0.3 million shares of common stock and 125,000 warrants with exercise price of $2.00 and a three-year term. The Company recorded a gain on settlement of $0.4 million to selling, general and administrative expenses on the condensed consolidated statement of operations for the three and nine months ended September 30, 2025.

​

Item 1A. Risk Factors

​

We are subject to various risks and uncertainties in the course of our business. In addition to other information contained elsewhere in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K filed with the SEC on March 24, 2025, which could materially affect our business, financial condition, or future results. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in the Annual Report.

​

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

​

Item 3. Defaults Upon Senior Securities

None.

​

Item 4. Mine Safety Disclosures

Not applicable.

​ 39

Table of Contents Item 5. Other Information

During the fiscal quarter ended September 30, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).

​

Item 6. Exhibits

See Exhibit Index.

​ 40

Table of Contents EXHIBIT INDEX

Exhibit No.	****	Description
2.1*	​	Business Combination Agreement, dated as of December 12, 2022, by and among Priveterra Acquisition Corp., Priveterra Merger Sub, Inc. and AEON Biopharma, Inc. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Priveterra Acquisition Corp. with the SEC on December 13, 2022)
2.1(a)*	​	Amendment No. 1 to Business Combination Agreement, dated as of April 27, 2023, by and among Priveterra Acquisition Corp., AEON Biopharma, Inc. and Priveterra Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Priveterra Acquisition Corp. with the SEC on May 1, 2023)
3.1	​	Third Amended and Restated Certificate of Incorporation of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Company with the SEC on July 27, 2023)
3.1.1	​	Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Company with the SEC on February 24, 2025)
3.2	​	Amended and Restated Bylaws of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.2 to the Form 8-K filed by the Company with the SEC on July 27, 2023)
3.2.1	​	Amendment to Amended and Restated Bylaws of AEON Biopharma, Inc. (incorporated by reference to Exhibit 3.1 to Form 8-K filed by the Company with the SEC on December 20, 2024)
4.1	​	Warrant Agreement, dated as of February 8, 2021, by and between Priveterra Acquisition Corp. and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 to the Form 10-K filed by Priveterra Acquisition Corp. with the SEC on March 28, 2022)
4.2	​	Specimen Warrant Certificate (incorporated by reference to Exhibit 4.2 to the Form 10-K filed by Priveterra Acquisition Corp. with the SEC on March 29, 2024)
4.3	​	Senior Secured Convertible Note, dated as of March 24, 2024, by and among AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD. and AEON Biopharma Sub, Inc. (incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company with the SEC on March 28, 2024)
4.4	​	Senior Secured Convertible Note, dated as of April 12, 2024, by and among AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD. and AEON Biopharma Sub, Inc. (incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company with the SEC on April 17, 2024)
4.5	​	Description of AEON Biopharma Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.5 to the Form 10-K filed by the Company with the SEC on August 12, 2024)
4.6	​	Form of Series A Warrant (incorporated by reference to Exhibit 4.1 to the Form 10-K filed by the Company with the SEC on January 7, 2025)
4.7	​	Form of Series B Warrant (incorporated by reference to Exhibit 4.2 to the Form 10-K filed by the Company with the SEC on January 7, 2025)
10.1†	​	Odeon Settlement Agreement October 2025
10.2†	​	Form of Odeon Warrants October 2025
31.1†	​	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2†	​	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1#	​	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2#	​	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS†	​	XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH†	​	XBRL Taxonomy Extension Schema Document
101.CAL†	​	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF†	​	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB†	​	XBRL Taxonomy Extension Label Linkbase Document
101.PRE†	​	XBRL Taxonomy Extension Presentation Linkbase Document
104†	​	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
†	Filed herewith.
---	---
*	The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.
---	---

41

Table of Contents

#

The certification attached as Exhibits 32.1 and 32.2 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of AEON Biopharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

​

​ 42

Table of Contents SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 14, 2025

​	​	​
​	AEON BIOPHARMA, INC.
​	​	​
​	By:	/s/ Robert Bancroft
​	Name:	Robert Bancroft
​	Title:	President and Chief Executive Officer
​	​	(Principal Executive Officer)
​	​	​
​	By:	/s/ Jennifer Sy
​	Name:	Jennifer Sy
​	Title:	Chief Accounting Officer
​	​	(Principal Financial and Accounting Officer)
​	​	​

​

​

​

​ 43

Exhibit 10.1

1<br>CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASE<br>This Settlement Agreement and Release (“Agreement”), dated October 31, 2025, is entered<br>into between Plaintiff Odeon Capital Group LLC (“Odeon” or “Plaintiff”) and Defendant AEON<br>Biopharma, Inc. (“AEON”) (collectively with Odeon referred to as the “Parties”).<br>RECITALS<br>WHEREAS, on September 18, 2023, Plaintiff filed its Complaint in the Supreme Court of<br>New York, New York County, in the litigation captioned Odeon Capital Group LLC v. AEON<br>Biopharma, Inc., formerly known as Priveterra Acquisition Corp., and Continental Stock Transfer<br>& Trust Company, bearing Index Number 654547/2023 (the “Action”); and<br>WHEREAS, the Parties desire to avoid the costs and uncertainty of further litigation and<br>agree to settle and resolve, completely and finally, all differences between Plaintiff and AEON, as<br>well as between Plaintiff and Continental Stock Transfer & Trust Company (“Continental”), and<br>all persons or entities released by this Agreement, without any admission of liability. This<br>includes, without limitation, a desire to resolve completely and finally all claims made and raised by<br>Plaintiff in the Action, against both AEON and Continental; and<br>WHEREAS, the Parties were represented by counsel throughout the Action and during all<br>settlement negotiations which resulted in the settlement of the Action and formulation of this<br>Agreement; and<br>NOW, THEREFORE, in consideration of the sum as outlined below (the<br>“Consideration”) and other good and fair consideration, the Parties have reached a full and final<br>compromise and settlement of any and all matters in controversy, disputes, causes of action, claims,<br>contentions, and differences between them, and between Plaintiff and Continental, and hereby agree<br>and understand as follows:
2<br>1. Mutual Release of the Parties and Release of Continental. Plaintiff, AEON, and<br>Continental individually and on behalf of themselves, their beneficiaries, heirs, administrators,<br>representatives, executors, children, successors and assigns hereby knowingly and voluntarily<br>releases, acquits, and forever discharges the other individually and on behalf of their present and<br>former subsidiaries, affiliates, members, managers, directors, officers, employees, agents, advisors,<br>consultants, representatives, shareholders, insurers and attorneys, and their heirs, successors, and<br>assigns (whether or not acting within the scope of their duties) from all claims of any nature<br>whatsoever which Plaintiff, AEON or Continental now has or asserts to have, or which Plaintiff,<br>AEON, or Continental at any time heretofore had, or asserted to have against the other arising out<br>of or in any way related in any way to any acts, circumstances, facts, transactions, omissions or other<br>subject matters, based on facts occurring prior to the date of this Agreement.<br>Plaintiff, AEON, and Continental specifically releases the following claims: Any and all past,<br>present or future claims, demands, obligations, actions, causes of action, rights, damages, costs, loss<br>of services, expenses, and compensation of any nature whatsoever based on a tort, contract, or other<br>theory of recovery, and whether for compensatory or punitive damages Plaintiff, AEON, or<br>Continental may now have, or which may hereafter accrue or otherwise be acquired against the<br>other’s agents, servants and employees directly or indirectly, including by way of example those<br>which may be or could have been the subject matter of a lawsuit pending in the Supreme Court of<br>New York, New York County, in the Action captioned Odeon Capital Group LLC v. AEON<br>Biopharma, Inc., formerly known as Priveterra Acquisition Corp., and Continental Stock Transfer<br>& Trust Company, bearing the Index Number 654547/2023. This Mutual Release is for<br>compensation of any and all injuries Plaintiff, AEON or Continental has sustained, known or<br>unknown, or unknowable related to the claims asserted in the Action. It is expressly understood that<br>this Mutual Release is for the settlement, release, discharge, and elimination of any and all such
---
3<br>claims. Plaintiff, AEON, and Continental hereby acknowledge that by executing this Mutual<br>Release and accepting the consideration paid hereunder Plaintiff, AEON, Continental and those who<br>otherwise might be entitled to make such a claim or claims in the future has received fair, just and<br>adequate compensation for all such claims in exchange for which all such claims, past, present and<br>future are forever released and discharged. Even if additional facts become known which were not<br>known at the time this Release was executed, Plaintiff, AEON, and Continental waives its right to<br>bring a lawsuit against the other for any injuries alleged to have been caused due to the actions and<br>conduct alleged in the Complaint filed by Plaintiff in the Action.<br>Nothing herein shall release (i) obligations under this Agreement; (ii) any rights or<br>obligations arising after the Effective Date; or (iii) claims for breach of this agreement.<br>2. Dismissal of Action. Plaintiff will file a Stipulation of Discontinuance of the Action,<br>with prejudice, within five (5) days of receipt of the Consideration as set forth in Section 3 of this<br>Agreement. This Agreement is expressly conditioned upon full and proper execution of the<br>Stipulation for Discontinuance and the filing thereof.<br>3. Consideration. In consideration for Plaintiff making the Release as set forth above, and<br>other good and fair consideration, AEON agrees to (i) pay Plaintiff the sum of $1,000,000 (ONE<br>MILLION DOLLARS AND ZERO CENTS) payable to Odeon Capital Group LLC; (ii) transfer to<br>Odeon shares of AEON Class A common stock equal to U.S.$250,000 based on a weighted volume<br>average price for the five trading days immediately following the execution of this Agreement,<br>subject to a $0.50 per share floor; and (iii) issue to Odeon a Warrant to Purchase up to 125,000 shares<br>of AEON’s Class A common stock, with said form and terms of such Warrants as set forth on Exhibit<br>A hereto. The Consideration set forth above shall be delivered within twenty (20) days of the full<br>execution of this Agreement, and receipt by AEON of wire instructions and a W-9. For the avoidance
---
4<br>of doubt, Continental is not undertaking any obligation regarding the settlement, other than as<br>expressly set forth in the Agreement.<br>4. Representations and Warranties. (a) Plaintiff and AEON represent and warrant that they have the full right, power and<br>authority to execute, deliver and perform this Settlement Agreement.<br>(b) Plaintiff and AEON represent and warrant that their signatory has the full authority<br>to enter into this Settlement Agreement and bind the party that it represents.<br>(c) Plaintiff and AEON represent and warrant that they are relying on their own counsel<br>and advice that each has received from its attorneys in executing this Settlement Agreement.<br>(d) Plaintiff acknowledges and agrees that any shares of AEON Class A common stock<br>issued pursuant to the Agreement (the “Settlement Shares”) are subject to a resale limitations such<br>that Odeon shall not, directly or indirectly, sell, transfer, or otherwise dispose of, in any public or<br>private transaction, shares of AEON Class A common stock in any calendar week in an amount<br>exceeding ten percent (10%) of the total number of Settlement Shares originally issued to Odeon<br>hereunder (the “Weekly Limit”). Sales or transfers in violation of this provision shall be null and<br>void and of no effect, and AEON shall be entitled to take all necessary actions to prevent or reverse<br>any such sale, including instructing its transfer agent to decline to process or record any transfer<br>inconsistent with the Weekly Limit or seeking injunctive relief.<br>(e) Plaintiff agrees not to perfect any appeal relating to or arising from the Action<br>against Continental.<br>5. Bound Parties. The Parties are bound by this Settlement and Release. This Agreement<br>shall be binding upon and the benefits shall inure to AEON and their respective successors and<br>assigns, as well as to Plaintiff and Plaintiff’s successors, assigns and representatives.
---
5<br>6. Entire Agreement. The Parties agree that this Agreement constitutes the entire agreement<br>between the Parties and that any amendment must be in writing and executed by both parties.<br>7. Notices. All notices, demands, requests, consents, approvals, or other communications<br>required or permitted under this Agreement (“Notices”) shall be in writing and shall be deemed duly<br>given and effective upon delivery by email or overnight courier service. Notices shall be directed to<br>each Party’s respective litigation counsel of record in the Action, and delivery to such counsel shall<br>constitute valid and effective notice to that Party.<br>8. Tax Treatment. Each Party shall be solely responsible for any and all taxes, assessments,<br>or other liabilities that may be imposed on it arising out of or relating to the Consideration provided<br>under this Agreement. AEON shall have no obligation to withhold, collect, or remit any taxes on<br>behalf of Plaintiff, and Plaintiff agrees to indemnify and hold AEON harmless from and against<br>any claim, liability, penalty, or expense (including reasonable attorneys’ fees) arising from or<br>relating to any such taxes. The Parties acknowledge and agree that no portion of the Consideration<br>constitutes wages, salary, or other compensation for services rendered, and that Plaintiff has not<br>relied on AEON for any tax advice in connection with this Agreement. Plaintiff further represents<br>that it has consulted with its own tax advisors regarding the tax consequences of this settlement.<br>9. Disclaimer of Liability. The Parties acknowledge and agree that the execution of this<br>Agreement shall not be considered an admission of liability or of responsibility by AEON<br>concerning any of the claims referred to herein, and no past or present wrongdoing on the part of<br>any of the Parties to this Agreement shall be implied by such payment or execution.<br>10. Nonadmissibility. This Agreement shall not be admissible in any legal proceeding except<br>to the extent Court approval of the settlement is required or to enforce the terms of the Agreement.<br>nor shall the terms herein prejudice any party hereto in any other proceeding.
---
6<br>11. Representation/Authority. The Parties acknowledge that they have been represented in<br>negotiations for, and in the preparation of, this Agreement by counsel of their choosing. The Parties<br>represent that they have read this Agreement, know and understand the terms of this Agreement<br>and its legal effect, that they have executed it voluntarily, that they have not been influenced by<br>any persons or other parties, and that they have authority to sign this Agreement. Accordingly, the<br>Parties expressly agree that any rule of law, including, but not limited to, the doctrine of contra<br>proferentum, or any legal decision that would require a legal interpretation of any claimed<br>ambiguities in this Agreement against the party that drafted it, has no application.<br>12. Partial Invalidity. If any term or provision of this Agreement is held by any court of<br>competent jurisdiction to be invalid or unenforceable, such invalidity or unenforceability shall not<br>invalidate the total Agreement. Instead, this Agreement shall be construed as if it did not contain<br>such term or provision, and the remainder of this Agreement shall remain in full force and effect.<br>13. Choice of Law, Venue, and Waiver of Jury Trial. The Parties agree that this Agreement<br>shall be interpreted, enforced and governed by the laws of the State of New York and that any<br>dispute concerning this agreement shall be brought in the New York Supreme Court, New York<br>County.<br>14. Counterparts. This Agreement may be executed in counterparts, each of which when so<br>executed shall be deemed to be an original, and such counterparts together shall constitute one and<br>the same Agreement. A faxed or electronically transmitted signature shall bear the same force and<br>effect as an original signature. The Parties nevertheless expressly agree that they will promptly<br>provide the other with a duly signed copy of this Agreement bearing the original signature of such<br>respective party.<br>THE PARTIES REPRESENT THAT THEY FULLY UNDERSTAND THEIR RIGHT TO<br>DISCUSS ALL ASPECTS OF THIS AGREEMENT WITH THEIR PRIVATE ATTORNEYS<br>AND THAT THEY HAVE, PRIOR TO EXECUTING THIS DOCUMENT, FULLY INFORMED<br>THEMSELVES OF ITS CONTENTS THROUGH ATTORNEYS, ADVISORS AND/OR
---
7<br>SOURCES OF THEIR OWN SELECTION. THE PARTIES ALSO REPRESENT THAT THEY<br>HAVE CAREFULLY READ AND FULLY UNDERSTAND ALL THE PROVISIONS OF THIS<br>AGREEMENT AND ARE VOLUNTARILY ENTERING INTO THIS AGREEMENT.<br>EACH PERSON SIGNING BELOW ON BEHALF OF ANY ENTITY HEREBY PERSONALLY<br>AND EXPRESSLY REPRESENTS AND WARRANTS THAT HE OR SHE IS SIGNING ON<br>BEHALF OF SUCH ENTITY WITH FULL LEGAL AUTHORITY TO BIND SUCH PARTY<br>TO EACH AND EVERY PROVISION OF THIS AGREEMENT:<br>Odeon Capital Group LLC, Dated:<br>Print Name<br>AEON Biopharma, Inc.<br>Dated:<br>By: Robert Bancroft<br> CEO & President<br>Continental Stock Transfer & Trust Company*<br>*As to Mutual Release Only<br>Dated:<br>Print Name<br>/s/ Evan Schwartzbert<br>Evan Schwartzbert, CEO<br>10/31/2025<br>/s/ Robert Bancroft 11/5/2025<br>Steven G. Nelson<br>10/31/2025 /s/ Steven G. Nelson
---

Exhibit 10.2

US-DOCS\165267476.1<br>THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE<br>EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN<br>REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE<br>“SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED<br>STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY<br>NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES<br>HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II)<br>SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III) THE COMPANY<br>HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT<br>THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION<br>UNDER THE SECURITIES ACT, OR (IV) THE SECURITIES ARE TRANSFERRED<br>WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A<br>CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL<br>REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).<br>FORM OF WARRANT TO PURCHASE CLASS A COMMON STOCK<br>Number of Shares:<br>[125,000] (subject to<br>adjustment)<br>Original Issue Date: [•], 2025<br>AEON Biopharma, Inc., a Delaware corporation (the “Company”), hereby certifies that,<br>for good and valuable consideration, the receipt and sufficiency of which are hereby<br>acknowledged, [•] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth<br>below, to purchase from the Company up to a total of [125,000] shares of Class A common stock,<br>$0.0001 par value per share (the “Common Stock”), of the Company (each such share, a<br>“Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal<br>to $[2.00] (the “Exercise Price”), in each case as adjusted from time to time as provided in Section<br>9, upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase<br>Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time<br>and from time to time on or after the date hereof (the “Initial Exercise Date”) and on or prior to<br>5:00 p.m. (New York City time) on [  ], 20281 (the “Termination Date”) but not thereafter.<br>1. Definitions. For purposes of this Warrant, the following terms shall have the<br>following meanings:<br>“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly<br>through one or more intermediates, controls, is controlled by or is under common control with<br>such Person.<br>1 Insert the date that is the three-year anniversary of the issuance date, provided that, if such date is not a Trading<br>Day, insert the immediately following Trading Day
US-DOCS\165267476.1<br>2<br>“Attribution Parties” means, collectively, the following Persons and entities: (i) any direct<br>or indirect Affiliates of the Holder, (ii) any Person acting or who could be deemed to be acting as a<br>Group together with the Holder or any Attribution Parties and (iii) any other Persons whose beneficial<br>ownership of the Company’s Common Stock would or could be aggregated with the Holder’s and/or<br>any other Attribution Parties for purposes of Section 13(d) or Section 16 of the Exchange Act. For<br>clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution<br>Parties to the Maximum Percentage.<br>“Closing Sale Price” means, for any security as of any date, the last trade price for such<br>security on the Principal Trading Market for such security, as reported by Bloomberg Financial<br>Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does<br>not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New<br>York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the<br>last trade price of such security in the over-the-counter market on the electronic bulletin board for<br>such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be<br>calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price<br>of such security on such date shall be the fair market value as mutually determined by the Company<br>and the Holder. All such determinations shall be appropriately adjusted for any stock dividend,<br>stock split, stock combination or other similar transaction during the applicable calculation period.<br>“Commission” means the U.S. Securities and Exchange Commission.<br>“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and all of<br>the rules and regulations promulgated thereunder.<br>“Group” shall have the meaning ascribed to it in Section 13(d) of the Exchange Act, and<br>all related rules, regulations and jurisprudence.<br>“Person” means an individual, partnership, corporation, limited liability company,<br>business trust, joint stock company, trust, unincorporated association, joint venture or any other<br>entity or organization.<br>“Principal Trading Market” means the national securities exchange or other trading<br>market on which the Common Stock is primarily listed on and quoted for trading, which, as of the<br>Original Issue Date, shall be the NYSE American.<br>“Securities Act” means the U.S. Securities Act of 1933, as amended, and all of the rules<br>and regulations promulgated thereunder.<br>“Standard Settlement Period” means the standard settlement period, expressed in a<br>number of Trading Days, for the Principal Trading Market with respect to the Common Stock that<br>is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issue<br>Date was “T+1.”<br>“Trading Day” means any weekday on which the Principal Trading Market is normally<br>open for trading.
---
US-DOCS\165267476.1 3<br>“Transfer Agent” means Continental Stock Transfer and Trust Company, the Company’s<br>transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.<br>2. Issuance of Securities; Registration of Warrants. The Company shall register<br>ownership of this Warrant, upon records to be maintained by the Company for that purpose (the<br>“Warrant Register”), in the name of the record Holder (which shall include the initial Holder or,<br>as the case may be, any assignee to which this Warrant is permissibly assigned hereunder) from<br>time to time. The Company may deem and treat the registered Holder of this Warrant as the<br>absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and<br>for all other purposes, absent actual notice to the contrary.<br>3. Registration of Transfers. This Warrant and all rights hereunder (including,<br>without limitation, any registration rights) are transferable, in whole or in part, upon surrender of<br>this Warrant at the principal office of the Company or its designated agent, together with a written<br>assignment of this Warrant substantially in the form attached hereto duly executed by the Holder<br>or its agent or attorney. Subject to compliance with all applicable securities laws, the Company<br>shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant<br>in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer<br>taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock<br>in substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing<br>the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant<br>evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the<br>transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed<br>the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant<br>that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent<br>to, prepare, issue and deliver at the Company’s own expense any New Warrant under this Section<br>3. Until due presentment for registration of transfer, the Company may treat the registered Holder<br>hereof as the owner and holder for all purposes, and the Company shall not be affected by any<br>notice to the contrary.<br>4. Exercise of Warrants.<br>(a) All or any part of this Warrant shall be exercisable by the registered Holder<br>in any manner permitted by this Warrant (including Section 11) at any time and from time to time<br>on or after the Initial Exercise Date and on or before the Termination Date.<br>(b) The Holder may exercise this Warrant by delivering to the Company (i) an<br>exercise notice, in the form attached as Schedule 1 hereto (the “Exercise Notice”), completed and<br>duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which<br>this Warrant is being exercised (which may take the form of a “cashless exercise” if so indicated<br>in the Exercise Notice pursuant to Section 10 below), and the date on which the last of such items<br>is delivered to the Company (as determined in accordance with the notice provisions hereof) is an<br>“Exercise Date.” The Holder shall not be required to deliver the original Warrant in order to effect<br>an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as<br>cancellation of the original Warrant and issuance of a New Warrant evidencing the right to<br>purchase the remaining number of Warrant Shares, if any. The Holder and the Company shall
---
US-DOCS\165267476.1<br>4<br>maintain records showing the number of Warrant Shares purchased and the date of such purchases.<br>The Company shall deliver any objection to any Notice of Exercise within two (2) Trading Days<br>of receipt of such notice.<br>(c) The Holder and any assignee, by acceptance of this Warrant, acknowledge<br>and agree that, by reason of the provisions of this section, following the purchase of a portion of<br>the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at<br>any given time may be less than the amount stated on the face hereof.<br>5. Delivery of Warrant Shares.<br>(a) Upon exercise of this Warrant, the Company shall promptly (but in no event<br>later than the number of Trading Days comprising the Standard Settlement Period following the<br>Exercise Date), upon the request of the Holder, cause the Transfer Agent to credit such aggregate<br>number of shares of Common Stock specified by the Holder in the Exercise Notice and to which the<br>Holder is entitled pursuant to such exercise (the “Exercise Shares”) to (i) the Holder’s or its<br>designee’s balance account with The Depository Trust Company (“DTC”) through its Deposit<br>Withdrawal At Custodian system or (ii) in book-entry form via a direct registration system (“DRS”)<br>maintained by or on behalf of the Transfer Agent, in each case, so long as either (A) there is an<br>effective registration statement permitting the issuance of the Warrant Shares to or the resale of such<br>Warrant Shares by the Holder or (B) the Exercise Shares are eligible for resale by the Holder without<br>volume or manner-of-sale restrictions pursuant to Rule 144 promulgated under the Securities Act<br>(assuming cashless exercise of this Warrant). If (A) and (B) above are not true, the Company shall<br>cause the Transfer Agent to either (i) record the Exercise Shares in the name of the Holder or its<br>designee on the certificates reflecting the Exercise Shares with an appropriate legend regarding<br>restriction on transferability, which shall be issued and dispatched by overnight courier to the address<br>as specified in the Exercise Notice, and on the Company’s share register or (ii) issue such Exercise<br>Shares in the name of the Holder or its designee in restricted book-entry form in the Company’s<br>share register. The Company agrees to maintain a transfer agent that is a participant in the FAST<br>program of the DTC so long as this Warrant remains outstanding and exercisable. The Holder, or<br>any Person so designated by the Holder to receive Warrant Shares, shall be deemed to have become<br>the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such<br>Warrant Shares are credited to the Holder’s or its designees’ DTC account, the date of the book entry<br>positions or the date of delivery of the certificates evidencing such Exercise Shares, as the case may<br>be.<br>(b) In addition to any other rights available to the Holder, if the Company fails<br>to cause the Transfer Agent to deliver to the Holder or its designee Exercise Shares in the manner<br>required pursuant to Section 5(a) within the Standard Settlement Period following the Exercise Date<br>(other than a failure caused by incorrect or incomplete information provided by the Holder to the<br>Company) and the Holder or the Holder’s broker on its behalf purchases (in an open market<br>transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder<br>of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”) but<br>did not receive within the Standard Settlement Period, then the Company shall, within two (2)<br>Trading Days after the Holder’s request and in the Holder’s sole discretion, promptly honor its<br>obligation to deliver to the Holder or its designee the Exercise Shares pursuant to Section 5(a) and<br>pay cash to the Holder in an amount equal to the excess (if any) of Holder’s total purchase price
---
US-DOCS\165267476.1 5<br>(including brokerage commissions, if any) for the shares of Common Stock so purchased in the<br>Buy-In, less the product of (A) the number of shares of Common Stock purchased in the Buy-In,<br>times (B) the difference between the Closing Sale Price of a share of Common Stock on the Exercise<br>Date and the price per shares realized by the Holder upon a sale of the Warrant Shares to cover the<br>exercise. The Holder shall provide the Company written notice promptly after the occurrence of a<br>Buy-In, indicating the amounts payable to the Holder in respect of the Buy-In together with<br>applicable confirmations and other evidence reasonably requested by the Company.<br>(c) To the extent permitted by law and subject to Section 5(b), the Company’s<br>obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof<br>(including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective<br>of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any<br>provision hereof, the recovery of any judgment against any Person or any action to enforce the same,<br>or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach<br>by the Holder or any other Person of any obligation to the Company or any violation or alleged<br>violation of law by the Holder or any other Person, and irrespective of any other circumstance that<br>might otherwise limit such obligation of the Company to the Holder in connection with the<br>issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder’s right<br>to pursue any other remedies available to it hereunder, at law or in equity including, without<br>limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s<br>failure to timely deliver Exercise Shares; provided, however, that the Holder shall not be entitled<br>to both (i) require the Company to reinstate the portion of the Warrant and equivalent number of<br>Warrant Shares for which such exercise was not timely honored and (ii) receive the number of<br>shares of Common Stock that would have been issued if the Company had timely complied with<br>its delivery requirements under Section 5(a).<br>6. Charges, Taxes and Expenses. Issuance and delivery of Exercise Shares shall be<br>made without charge to the Holder for any issue or transfer tax, transfer agent fee or other<br>incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such<br>shares, all of which taxes and expenses shall be paid by the Company; provided, however, that the<br>Company shall not be required to pay any tax that may be payable in respect of any transfer<br>involved in the registration of any Warrant Shares or the Warrants in a name other than that of the<br>Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may<br>arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise<br>hereof.<br>7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed,<br>the Company shall issue or cause to be issued in exchange and substitution for and upon<br>cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon<br>receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in<br>such case) and, in each case, a customary and reasonable contractual indemnity, if requested by<br>the Company. If a New Warrant is requested as a result of a mutilation of this Warrant, then the<br>Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the<br>Company’s obligation to issue the New Warrant.<br>8. Reservation of Warrant Shares. The Company covenants that it will, at all times<br>while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized
---
US-DOCS\165267476.1 6<br>but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue<br>Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that<br>are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive<br>rights or any other contingent purchase rights of persons other than the Holder (taking into account<br>the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so<br>issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in<br>accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that<br>such shares of Common Stock may be issued as provided herein without violation of any applicable<br>law or regulation, or of any requirements of any securities exchange or automated quotation system<br>upon which the Common Stock may be listed. The Company further covenants that it will not,<br>without the prior written consent of the Holder, take any actions to increase the par value of the<br>Common Stock at any time while this Warrant is outstanding.<br>9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable<br>upon exercise of this Warrant (the “Number of Warrant Shares”) are subject to adjustment from<br>time to time as set forth in this Section 9.<br>(a) Stock Dividends and Splits. If the Company, at any time while this Warrant<br>is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on<br>any class of capital stock issued and outstanding on the Original Issue Date and in accordance with<br>the terms of such stock on the Original Issue Date or as amended, that is payable in shares of<br>Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of<br>shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller<br>number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any<br>additional shares of Common Stock of the Company, then in each such case the Number of Warrant<br>Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of<br>Common Stock outstanding immediately after such event and the denominator of which shall be<br>the number of shares of Common Stock outstanding immediately before such event. Any adjustment<br>made pursuant to clause (i) of this paragraph shall become effective immediately after the record<br>date for the determination of stockholders entitled to receive such dividend or distribution, provided,<br>however, that if such record date shall have been fixed and such dividend is not fully paid on the<br>date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close<br>of business on such record date and thereafter the Number of Warrant Shares shall be adjusted<br>pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment<br>pursuant to clause (ii), (iii) or (iv) of this paragraph shall become effective immediately after the<br>effective date of such subdivision, combination or issuance.<br>(b) Pro Rata Distributions. If, on or after the Original Issue Date, the Company<br>shall declare or make any dividend or other pro rata distribution of its assets (or rights to acquire<br>its assets) to holders of shares of Common Stock, by way of return of capital or otherwise<br>(including, without limitation, any distribution of cash, stock or other securities, property, options,<br>evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification,<br>corporate rearrangement, scheme of arrangement or other similar transaction, but, for the<br>avoidance of doubt, excluding any distribution of shares of Common Stock subject to Section 9(a),<br>any distribution of Purchase Rights (as defined below) subject to Section 9(c) and any Fundamental<br>Transaction (as defined below) subject to Section 9(d)) (a “Distribution”) then, in each such case,
---
US-DOCS\165267476.1 7<br>the Holder shall be entitled to participate in such Distribution to the same extent that the Holder<br>would have participated therein if the Holder had held the number of shares of Common Stock<br>acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions<br>on exercise of this Warrant, including without limitation, the Maximum Percentage (as defined<br>below)) immediately before the date on which a record is taken for such Distribution, or, if no such<br>record is taken, the date as of which the record holders of shares of Common Stock are to be<br>determined for the participation in such Distribution; provided, that to the extent that the Holder’s<br>right to participate in any such Distribution would result in the Holder and the other Attribution<br>Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in<br>such Distribution to such extent (and shall not be entitled to beneficial ownership of such shares of<br>Common Stock as a result of such Distribution to such extent) and the portion of such Distribution<br>shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto<br>would not result in the Holder and the other Attribution Parties exceeding the Maximum<br>Percentage, at which time or times the Holder shall be granted such Distribution (and any<br>Distributions declared or made on such initial Distribution or on any subsequent Distribution held<br>similarly in abeyance) to the same extent as if there had been no such limitation.<br>(c) Purchase Rights. If at any time on or after the Original Issue Date, the<br>Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock,<br>warrants, securities or other property, in each case pro rata to the record holders of any class of<br>Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms<br>applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have<br>acquired if the Holder had held the number of shares of Common Stock acquirable upon complete<br>exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant,<br>including without limitation, the Maximum Percentage) immediately before the date on which a<br>record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken,<br>the date as of which the record holders of Common Stock are to be determined for the grant, issuance<br>or sale of such Purchase Rights; provided, that to the extent that the Holder’s right to participate in<br>any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the<br>Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to<br>such extent (and shall not be entitled to beneficial ownership of such Common Stock as a result of<br>such Purchase Right (and beneficial ownership) to such extent) and at the Holder’s election, in its<br>sole discretion, either (1)such Purchase Right to such extent shall be held in abeyance for the benefit<br>of the Holder until such time or times as its right thereto would not result in the Holder and the other<br>Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be<br>granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or<br>on any subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there<br>had been no such limitation) or (2) the Company shall offer the Holder the right upon exercise of<br>such Purchase Right to acquire a security (e.g. a pre-funded warrant) that would not result in the<br>Holder and the other Attribution Parties exceeding the Maximum Percentage but will otherwise to<br>the extent possible have economic and other rights, preferences and privileges substantially<br>consistent and on par with the securities or other property issuable upon exercise of the originally<br>offered Purchase Rights. ). As used in this Section 9(c), (i) “Options” means any rights, warrants or<br>options to subscribe for or purchase shares of Common Stock or Convertible Securities and (ii)<br>“Convertible Securities” mean any stock or securities (other than Options) directly or indirectly<br>convertible into or exercisable or exchangeable for shares of Common Stock.
---
US-DOCS\165267476.1 8<br>(d) Fundamental Transactions. If, at any time while this Warrant is outstanding<br>(i) the Company effects any merger or consolidation of the Company with or into another Person,<br>in which the Company is not the surviving entity or in which the stockholders of the Company<br>immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50%<br>of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the<br>Company effects any sale to another Person of all or substantially all of its assets in one or a series<br>of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company<br>or another Person), holders of capital stock tender shares representing more than 50% of the voting<br>power of the capital stock of the Company and the Company or such other Person, as applicable,<br>accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or<br>other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than<br>50% of the voting power of the capital stock of the Company (except for any such transaction in<br>which the stockholders of the Company immediately prior to such transaction maintain, in<br>substantially the same proportions, the voting power of such Person immediately after the<br>transaction) or (v) the Company effects any reclassification of the Common Stock or any<br>compulsory share exchange pursuant to which the Common Stock is effectively converted into or<br>exchanged for other securities, cash or property (other than as a result of a subdivision or<br>combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a<br>“Fundamental Transaction”), then following such Fundamental Transaction the Holder shall have<br>the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or<br>property as it would have been entitled to receive upon the occurrence of such Fundamental<br>Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the<br>number of Warrant Shares then issuable upon exercise in full of this Warrant (including any<br>Distributions or Purchase Rights then held in abeyance pursuant to Sections 9(b) or 9(c) above)<br>without regard to any limitations on exercise contained herein (the “Alternate Consideration”).<br>The Company shall not effect any Fundamental Transaction in which the Company is not the<br>surviving entity or the Alternate Consideration includes securities of another Person unless (i) the<br>Alternate Consideration is solely cash and the Company provides for the simultaneous “cashless<br>exercise” of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the<br>consummation thereof, any successor to the Company, surviving entity or other Person (including<br>any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such<br>Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled<br>to receive, and the other obligations under this Warrant. The provisions of this paragraph (d) shall<br>similarly apply to subsequent transactions analogous to a Fundamental Transaction type. If the<br>Company undertakes a Fundamental Transaction in which the Company is not the surviving entity<br>and the Alternate Consideration includes securities of another Person, then the Company shall<br>provide that, prior to or simultaneously with the consummation of such Fundamental Transaction,<br>any successor to the Company, surviving entity or other Person (including any purchaser of assets<br>of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration<br>as the Holder is entitled to receive in accordance with the foregoing provisions, and to assume the<br>other obligations under this Warrant. The provisions of this paragraph (d) shall similarly apply to<br>subsequent transactions analogous of a Fundamental Transaction type.<br>(e) Number of Warrant Shares. Simultaneously with any adjustment to the<br>Number of Warrant Shares pursuant to Section 9, the Exercise Price shall be increased or decreased
---
US-DOCS\165267476.1 9<br>proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for<br>the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise<br>Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event<br>may the Exercise Price be adjusted below the par value of the Common Stock then in effect.<br>(f) Calculations. All calculations under this Section 9 shall be made to the<br>nearest one-tenth of one cent or the nearest share, as applicable.<br>(g) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to<br>this Section 9, the Company at its expense will, at the written request of the Holder, promptly<br>compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare<br>a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and<br>adjusted number or type of Warrant Shares or other securities issuable upon exercise of this<br>Warrant (as applicable), describing the transactions giving rise to such adjustments and showing<br>in detail the facts upon which such adjustment is based. Upon written request, the Company will<br>promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.<br>(h) Notice of Corporate Events. If, while this Warrant is outstanding, the<br>Company (i) declares a dividend or any other distribution of cash, securities or other property in<br>respect of its Common Stock, including, without limitation, any granting of rights or warrants to<br>subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or<br>approves, enters into any agreement contemplating or solicits stockholder approval for any<br>Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up<br>of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed<br>to constitute material non-public information, the Company shall deliver to the Holder a notice of<br>such transaction at least ten (10) days prior to the applicable record or effective date on which a<br>Person would need to hold Common Stock in order to participate in or vote with respect to such<br>transaction; provided, however, that the failure to deliver such notice or any defect therein shall<br>not affect the validity of the corporate action required to be described in such notice. In addition,<br>if while this Warrant is outstanding, the Company authorizes or approves, enters into any<br>agreement contemplating or solicits stockholder approval for any Fundamental Transaction<br>contemplated by Section 9(d), other than a Fundamental Transaction under clause (iii) of Section<br>9(d), then, except if such notice and contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental<br>Transaction at least thirty (30) days prior to the date such Fundamental Transaction is<br>consummated. Holder agrees to maintain any information disclosed pursuant to this Section 9(h)<br>in confidence until such information is publicly available, and shall comply with applicable law<br>with respect to trading in the Company’s securities following receipt of any such information.<br>(i) Voluntary Adjustment By Company. Subject to the rules and regulations of<br>the Principal Trading Market, the Company may at any time during the term of this Warrant,<br>reduce the then-current Exercise Price to any amount and for any period of time deemed<br>appropriate by the board of directors of the Company.<br>10. Payment of Exercise Price. Notwithstanding anything contained herein to the<br>contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price<br>through a “cashless exercise”, in which event the Company shall issue to the Holder the number
---
US-DOCS\165267476.1 10<br>of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities<br>Act, determined as follows:<br>X = Y [(A-B)/A]<br>where:<br>“X” equals the number of Warrant Shares to be issued to the Holder;<br>“Y” equals the total number of Warrant Shares with respect to which this Warrant<br>is then being exercised;<br>“A” equals the Closing Sale Price of the shares of Common Stock (as reported by<br>Bloomberg Financial Market) as of the Trading Day on the date immediately preceding<br>the Exercise Date; and<br>“B” equals the Exercise Price then in effect for the applicable Warrant Shares at<br>the time of such exercise.<br>For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and<br>acknowledged that the Warrant Shares issued in a “cashless exercise” transaction shall be deemed<br>to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed<br>to have commenced, on the Original Issue Date (provided that the Commission continues to take<br>the position that such treatment is proper at the time of such exercise). In the event that a registration<br>statement registering the issuance of Warrant Shares is, for any reason, not effective at the time of<br>exercise of this Warrant, then this Warrant may only be exercised through a cashless exercise, as<br>set forth in this Section 10. If the Warrant Shares are issued in such a cashless exercise, the<br>Company acknowledges and agrees that, in accordance with Section 3(a)(9) of the Securities Act,<br>the Exercise Shares issued in such exercise shall take on the registered characteristics of the<br>Warrants being exercised and may be tacked on to the holding period of the Warrants being<br>exercised. Except as set forth in Section 5(b) (Buy-in Remedy) and Section 12 (No Fractional<br>Shares), in no event will the exercise of this Warrant be settled in cash.<br>11. Limitations on Exercise.<br>(a) Notwithstanding anything to the contrary contained herein, the Company<br>shall not effect the exercise of any portion of this Warrant, and the Holder of this Warrant shall not<br>have the right to exercise any portion of the Warrant, and any such exercise shall be null and void<br>ab initio and treated as if the exercise had not been made, to the extent that immediately prior to or<br>following such exercise, the Holder, together with the Attribution Parties, beneficially owns or would<br>beneficially own as determined in accordance with Section 13(d) of the Exchange Act and the rules<br>promulgated thereunder, in excess of 9.99% (the “Maximum Percentage”) of the Common Stock<br>that would be issued and outstanding following such exercise. For purposes of calculating beneficial<br>ownership for determining whether the Maximum Percentage is or will be exceeded, the aggregate<br>number of shares of Common Stock held and/or beneficially owned by the Holder together with the<br>Attribution Parties, shall include the number of shares of Common Stock held and/or beneficially<br>owned by the Holder together with the Attribution Parties plus the number of shares of Common<br>Stock issuable upon exercise of the relevant Warrant with respect to which the determination is being
---
US-DOCS\165267476.1<br>11<br>made but shall exclude the number of shares of Common Stock which would be issuable upon (i)<br>exercise of the remaining, unexercised Warrant held and/or beneficially owned by the Holder or the<br>Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any<br>other securities of the Company held and/or beneficially owned by such Holder or any Attribution<br>Party (including, without limitation, any convertible notes, convertible stock or warrants) that are<br>subject to a limitation on conversion or exercise analogous to the limitation contained herein. For<br>purposes of this Paragraph 11(a), beneficial ownership of the Holder or the Attribution Parties shall,<br>except as set forth in the immediately preceding sentence, be calculated and determined in<br>accordance with Section 13(d) of the Exchange Act and the rules promulgated thereunder. For<br>purposes of this Warrant, in determining the number of outstanding shares of Common Stock, a<br>Holder of this Warrant may rely on the number of outstanding shares of Common Stock as reflected<br>in (1) the Company’s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other<br>public filing with the Securities and Exchange Commission, as the case may be, (2) a more recent<br>public announcement by the Company or (3) any other notice by the Company or the Company’s<br>transfer agent setting forth the number of shares of Common Stock outstanding (such issued and<br>outstanding shares, the “Reported Outstanding Share Number”). For any reason at any time, upon<br>the written or oral request of the Holder, the Company shall within one Trading Day confirm orally<br>and in writing or by electronic mail to the Holder the number of shares of Common Stock then<br>outstanding. The Holder shall disclose to the Company the number of shares of Common Stock that<br>it, together with the Attribution Parties holds and/or beneficially owns and has the right to acquire<br>through the exercise of derivative securities and any limitations on exercise or conversion analogous<br>to the limitation contained herein contemporaneously or immediately prior to submitting an Exercise<br>Notice for the relevant Warrant. If the Company receives an Exercise Notice from the Holder at a<br>time when the actual number of outstanding shares of Common Stock is less than the Reported<br>Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of<br>shares of Common Stock then outstanding and, to the extent that such Exercise Notice would<br>otherwise cause the Holder’s, together with the Attribution Parties’, beneficial ownership, as<br>determined pursuant to this Section 11(a), to exceed the Maximum Percentage, the Holder must<br>notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such<br>Exercise Notice (the number of shares by which such purchase is reduced, the “Reduction Shares”)<br>and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise price<br>paid by the Holder for the Reduction Shares. In any case, the number of outstanding shares of<br>Common Stock shall be determined after giving effect to the conversion or exercise of securities of<br>the Company, including this Warrant, by the Holder and the Attribution Parties since the date as of<br>which the Reported Outstanding Share Number was reported. In the event that the issuance of<br>Common Stock to the Holder upon exercise of this Warrant results in the Holder, together with the<br>Attribution Parties, being deemed to beneficially own, in the aggregate, more than the Maximum<br>Percentage of the number of outstanding shares of Common Stock (as determined under Section<br>13(d) of the Exchange Act), the number of shares so issued by which the Holder’s, together with<br>the Attribution Parties’, aggregate beneficial ownership exceeds the Maximum Percentage (the<br>“Excess Shares”) shall be deemed null and void and shall be cancelled ab initio, and the Holder<br>and/or the Attribution Parties shall not have the power to vote or to transfer the Excess Shares. As<br>soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and<br>void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess<br>Shares. By written notice to the Company, a Holder of this Warrant may from time to time increase<br>or decrease the Maximum Percentage to any other percentage not in excess of 19.99% specified
---
US-DOCS\165267476.1<br>12<br>in such notice; provided that any increase in the Maximum Percentage will not be effective until<br>the 61st day after such notice is delivered to the Company and shall not negatively affect any<br>partial exercise effected prior to such change.<br>(b) This Section 11 shall not restrict the number of shares of Common Stock<br>which a Holder or the Attribution Parties may receive or beneficially own in order to determine<br>the amount of securities or other consideration that such Holder or the Attribution Parties may<br>receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of this Warrant.<br>For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant<br>in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder<br>or the Attribution Parties for any purpose including for purposes of Section 13(d) of the Exchange<br>Act and the rules promulgated thereunder or Section 16 of the Exchange Act and the rules<br>promulgated thereunder, including Rule 16a-1(a)(1). No prior inability to exercise this Warrant<br>pursuant to this paragraph shall have any effect on the applicability of the provisions of this<br>paragraph with respect to any subsequent determination of exercisability. The provisions of this<br>paragraph shall be construed and implemented in a manner otherwise than in strict conformity<br>with the terms of this Section 11 to the extent necessary to correct this paragraph or any portion of<br>this paragraph which may be defective or inconsistent with the intended beneficial ownership<br>limitation contained in this Section 11 or to make changes or supplements necessary or desirable<br>to properly give effect to such limitation. The limitation contained in this paragraph may not be<br>waived and shall apply to a successor holder of this Warrant.<br>12. No Fractional Shares. No fractional Warrant Shares will be issued in connection<br>with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable,<br>the number of Warrant Shares to be issued shall be rounded down to the next whole number and<br>the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price)<br>for any such fractional shares.<br>13. Notices. Any and all notices or other communications or deliveries hereunder<br>(including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given<br>and effective on the earliest of (i) the date of transmission, if such notice or communication is<br>delivered confirmed e-mail at the e-mail address specified by the Company prior to 5:30 P.M., New<br>York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such<br>notice or communication is delivered via confirmed e-mail at the e-mail address specified by the<br>Company on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any<br>Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized<br>overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the<br>Person to whom such notice is required to be given, if by hand delivery.<br>14. Warrant Agent. The Company shall initially serve as warrant agent under this<br>Warrant. Upon 30 days’ notice to the Holder, the Company may appoint a new warrant agent. Any<br>corporation into which the Company or any new warrant agent may be merged or any corporation<br>resulting from any consolidation to which the Company or any new warrant agent shall be a party<br>or any corporation to which the Company or any new warrant agent transfers substantially all of its<br>corporate trust or shareholders services business shall be a successor warrant agent under this<br>Warrant without any further act. Any such successor warrant agent shall promptly cause notice of
---
US-DOCS\165267476.1 13<br>its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at<br>the Holder’s last address as shown on the Warrant Register.<br>15. Miscellaneous.<br>(a) No Rights as a Stockholder. Except as otherwise set forth in this Warrant, the<br>Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or<br>receive dividends or be deemed the holder of share capital of the Company for any purpose, nor<br>shall anything contained in this Warrant be construed to confer upon the Holder, solely in such<br>Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company<br>or any right to vote, give or withhold consent to any corporate action (whether any reorganization,<br>issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or<br>otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior<br>to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive<br>upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be<br>construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this<br>Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by<br>the Company or by creditors of the Company.<br>(b) Further Assurances. Except and to the extent as waived or consented to by<br>the Holder, the Company shall not by any action, including, without limitation, amending its<br>certificate or articles of incorporation or through any reorganization, transfer of assets,<br>consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid<br>or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all<br>times in good faith assist in the carrying out of all such terms and in the taking of all such actions<br>as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against<br>impairment. Without limiting the generality of the foregoing, the Company will (a) not increase<br>the par value of any Warrant Shares above the amount payable therefor upon such exercise<br>immediately prior to such increase in par value, (b) take all such action as may be necessary or<br>appropriate in order that the Company may validly and legally issue fully paid and non-assessable<br>Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to<br>obtain all such authorizations, exemptions or consents from any public regulatory body having<br>jurisdiction thereof as may be necessary to enable the Company to perform its obligations under<br>this Warrant. Before taking any action which would result in an adjustment in the number of<br>Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall<br>obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary<br>from any public regulatory body or bodies having jurisdiction thereof.<br>(c) Successors and Assigns. Subject to compliance with applicable securities<br>laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the<br>Company without the written consent of the Holder, except to a successor in the event of a<br>Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the<br>Company and the Holder and their respective successors and assigns. Subject to the preceding<br>sentence, nothing in this Warrant shall be construed to give to any Person other than the Company<br>and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This<br>Warrant may be amended only in writing signed by the Company and the Holder, or their<br>successors and assigns.
---
US-DOCS\165267476.1<br>14<br>(d) Amendment and Waiver. Except as otherwise provided herein, the<br>provisions of this Warrant may be amended and the Company may take any action herein<br>prohibited, or omit to perform any act herein required to be performed by it, only if the Company<br>has obtained the written consent of the Holder.<br>(e) Acceptance. Receipt of this Warrant by the Holder shall constitute<br>acceptance of and agreement to all of the terms and conditions contained herein.<br>(f) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE<br>CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS<br>WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN<br>ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD<br>TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY<br>AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE<br>JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW<br>YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE<br>HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION<br>CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO<br>THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY<br>IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR<br>PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE<br>JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER<br>HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS<br>TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY<br>MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT<br>DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN<br>EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE<br>GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING<br>CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO<br>SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY<br>AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.<br>(g) Headings. The headings herein are for convenience only, do not constitute<br>a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.<br>(h) Severability. If any part or provision of this Warrant is held unenforceable<br>or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or<br>unenforceable part or provisions shall be replaced with a provision which accomplishes, to the<br>extent possible, the original business purpose of such part or provision in a valid and<br>enforceable manner, and the remainder of this Warrant shall remain binding upon the parties<br>hereto.<br>[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
---
[Signature Page to Warrant]<br>IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by<br>its authorized officer as of the date first indicated above.<br>AEON Biopharma, Inc.<br>By:<br>Name:<br>Title:
---
US-DOCS\165267476.1<br>SCHEDULE 1<br>FORM OF EXERCISE NOTICE<br>[To be executed by the Holder to purchase shares of Common Stock under the Warrant]<br>Ladies and Gentlemen:<br>(1) The undersigned is the Holder of a Warrant issued by AEON Biopharma, Inc., a Delaware<br>corporation (the “Company”). Capitalized terms used herein and not otherwise defined herein<br>have the respective meanings set forth in the Warrant.<br>(2) The undersigned hereby exercises its right to purchase _____ Warrant Shares pursuant to the<br>Warrant.<br>(3) The Holder intends that payment of the Exercise Price shall be made as (check one):<br>☐ Cash Exercise<br>☐ “Cashless Exercise” under Section 10 of the Warrant<br>(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ _____ in<br>immediately available funds to the Company in accordance with the terms of the Warrant.<br>(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares<br>determined in accordance with the terms of the Warrant.<br>(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the<br>Company that in giving effect to the exercise evidenced hereby (i) the Holder is an “accredited<br>investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended<br>and (ii) the Holder will not beneficially own in excess of the number of shares of Common Stock<br>(as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as<br>amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.<br>Dated:<br>Name of Holder:<br>By:<br>Name:<br>Title:<br>(Signature must conform in all respects to name of Holder as specified on the face of the<br>Warrant)
---

Exhibit 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert Bancroft, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of AEON Biopharma, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
---	---
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
---	---
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
---	---
a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
---	---
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
---	---
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
---	---
d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
---	---
5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
---	---
a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
---	---
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
---	---
​	​
---	---	---	---
Dated: November 14, 2025	By:	/s/ Robert Bancroft
​	​	Name:	Robert Bancroft
​	​	Title:	President and Chief Executive Officer
​	​	​	(Principal Executive Officer)

​

​ Exhibit 31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jennifer Sy, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of AEON Biopharma, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
---	---
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
---	---
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
---	---
a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
---	---
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
---	---
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
---	---
d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
---	---
5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
---	---
a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
---	---
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
---	---
​	​
---	---	---	---
Dated: November 14, 2025	By:	/s/ Jennifer Sy
​	​	Name:	Jennifer Sy
​	​	Title:	Chief Accounting Officer
​	​	​	(Principal Financial and Accounting Officer)

​ ​

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

​

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of AEON Biopharma, Inc. (the “Company”) hereby certifies, to the best of my knowledge, that:

(i)	the accompanying Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2025 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934; as amended; and
(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
---	---
​	​
---	---	---	---
Dated: November 14, 2025	By:	/s/ Robert Bancroft
​	​	Name:	Robert Bancroft
​	​	Title:	President and Chief Executive Officer
​	​	​	(Principal Executive Officer)

​

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

​ Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of AEON Biopharma, Inc. (the “Company”) hereby certifies, to the best of my knowledge, that:

(i)	the accompanying Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2025 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934; as amended; and
(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
---	---
​	​
---	---	---	---
Dated: November 14, 2025	By:	/s/ Jennifer Sy
​	​	Name:	Jennifer Sy
​	​	Title:	Chief Accounting Officer
​	​	​	(Principal Financial and Accounting Officer)

​

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. ​